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Abstract: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous sys-
tem (CNS) that afflicts over 2 million people worldwide. On the basis of the temporal course of disease, MS 
can be subdivided into three clinical groups: relapsing remitting MS (RR-MS), secondary progressive MS and 
primary progressive MS. There is a high degree of clinical diversity within these subgroups. The pathogenesis 
of MS in most patients is likely to result from autoreactive, activated CD4
+
 T cells moving from the periphery 
across the blood brain barrier into the CNS. Most therapeutic agents used in MS (e.g. immunosuppressive and 
immunomodulatory drugs and cell cycle interruption drugs) are only used for RR-MS. These treatments show 
some efficiency in lessening the relapse rate in RR-MS and time to progression, but cannot cure MS. Thus, 
there is a need for new efficient treatments for all types of MS. An increasing number of studies indicate that 
nuclear factor-?B plays an important role in controlling expression of genes relevant to the pathogenesis of 
autoimmunity. Genetic factors related to NF-?B may also be determinants of MS susceptibility, as polymor-
phisms in the molecules involved in regulation of the NF-?B signal transduction pathway differ between RR-
MS and progressive MS. Herein, the role of NF-?B in MS will be reviewed and its potential as a new thera-
peutic target in MS will be considered and compared with existing treatments. 
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1. MULTIPLE SCLEROSIS 
 Multiple sclerosis (MS) is a chronic inflamma-
tory, demyelinating and neurodegenerative disor-
der of the central nervous system (CNS) of un-
known etiology [1] that affects about 0.2% of the 
world population [2]. Based on the cells that make 
up the inflammatory infiltrate in the CNS during 
MS, and on the study of experimental autoimmune 
encephalomyelitis (EAE), MS is considered to be 
an autoimmune disease mediated primarily by 
CD4
+
 T cells [3, 4]. The pathological hallmarks of 
MS are demyelination and axonal damage. De-
myelinated lesions can occur anywhere within the 
brain and spinal cord, leading to disease complex-
ity and heterogeneity of clinical signs and symp-
toms. The latter can include problems with vision  
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(e.g. optic neuritis, nystagmus), with motor (e.g. 
paresis, monoparesis, dysarthria) or sensory (e.g. 
paraesthesia, neuralgia, anaesthesia) function, co-
ordination and balance (e.g. ataxia, intention 
tremor, vertigo), cognitive function (e.g. depres-
sion, dementia) and problems with bladder and 
bowel functions. 
Clinical Course of MS 
 On the basis of the temporal course of disease, 
MS can be subdivided into three main clinical 
subgroups: relapsing–remitting MS (RR-MS), sec-
ondary progressive MS (SP-MS) and primary pro-
gressive MS (PP-MS) [5] (Table 1). In RR-MS, 
which is the initial disease course in more than 
80% of patients, exacerbation of neurological 
symptoms are followed by complete or incomplete 
remission [6]. RR-MS is twice as prevalent in fe-
males as in males. With time, about half of those 
patients who initially have RR-MS develop SP-
MS, in which there is a continuous, irreversible 
neurological decline unassociated with relapses [6-
8]. 
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 Ten to 15% of patients with MS have a primary 
progressive disease course from the onset. Clini-
cally, PP-MS is defined as a disease course with-
out any clinical attacks or remission from onset [6, 
9]. The incidence of PP-MS is similar in females 
and males and PP-MS tends to appear at a later 
age than does RR-MS. Although at first sight PP-
MS and SP-MS are quite different [10-12], these 
two clinical groups share some features [13-15] 
and it has been suggested that PP-MS is MS “am-
putated” from the usual preceding relapsing-
remitting phase [16]. In addition to these three ma-
jor clinical MS subgroups, a small number of pa-
tients initially present as PP-MS, but later develop 
neurologic exacerbations [17]. This pattern of dis-
ease is usually called progressive relapsing MS 
(PR-MS). However, this term has also been used 
for patients with SP-MS who have clinical exacer-
bations followed by incomplete remission [6]. 
Pathogenesis of MS 
 MS is generally considered to be an autoim-
mune disease directed against CNS myelin and the 
myelin-producing cells, the oligodendrocytes; 
however, as with many other human chronic auto-
immune diseases, the primary cause of autoimmu-
nity is unknown. Most studies in people with MS 
and from the animal model of MS, EAE, which 
shares some of the clinical and neuropathological 
features of MS, suggest that Th1 and Th17 CD4
+
 
cells are important in the initiation of episodes of 
demyelination in the relapsing-remitting phase of 
MS [3, 18-24]. Several studies have also proposed 
a role for CD8
+
 T cells in the subsequent stages of 
Table 1. Differences Between RR-MS and Chronic Progressive MS 
 
 RR-MS SP-MS PP-MS 
Mean age of onset (years) 30  40  40  
Female:male ratio 2-3:1 2-3:1 1:1 
Presenting syndrome 
Optic nerve (25%) 
Brainstem (20%) 
Spinal cord (45% - sensory 
more common than motor) 
 
Spinal cord (80% - motor much more 
common than sensory) 
Brainstem and cerebellum (15%) 
Brain lesions on MRI Moderate Moderate Small 
Gadolinium-enhancing le-
sions 
Common Common Infrequent 
Healthy looking white-matter 
injury 
No Mild Prominent 
Spinal cord atrophy [171] Limited Yes Yes 
Typical lesions [172,173] 
Focal inflammatory primary 
demyelinating lesions with 
relative sparing of axons. In-
flammatory infiltrate made up 
of T cells, B cells, macro-
phages, activated microglia. 
Less active inflamma-
tion in focal white mat-
ter lesions. Diffuse 
axonal injury 
Less active inflammation in focal white 
matter lesions. Diffuse axonal injury. Loss 
of oligodendrocytes. 
Antibodies & complement 
activation [172-174] 
Yes Yes Yes 
Presence of B-cell follicle-
like structures in meninges 
[15] 
No Yes No 
Cortical demyelination [175] Mild Mild to prominent Prominent 
Autoimmune reactivity to 
myelin antigens by blood and 
CSF cells [19,176,177] 
Yes 
Yes (but usually less 
than in RR-MS) 
Limited 
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disease [25, 26]. The activity of these pathogenic 
T cells is regulated by special regulatory T cells 
(Treg), which have been reported to be reduced in 
number and dysfunctional in the peripheral blood 
of people with MS [27, 28], but increased in num-
ber in the CNS [29]. The progressive stage of MS 
is believed to be secondary to neurodegenerative 
changes triggered by inflammation. Additionally, 
there is increased formation of B-cell follicular-
like structures in the CNS in progressive MS, 
strongly suggesting a prominent role for B cells 
and antibodies in the development of disease pro-
gression [15, 30]. 
 A central player in the activation of T cells and 
other cells thought to be involved in the patho-
genesis of MS, including B cells, dendritic cells 
(DC), macrophages, and CNS resident glia, is the 
transcription factor NF-?B. NF-?B is induced by a 
large number of extracellular signals involved in 
both innate and adaptive immune responses, and is 
an important mediator in activation of T cells and 
their expression of pro-inflammatory cytokines, 
production of antibody by B cells, cytokine pro-
duction by DC and macrophages, and in the regu-
lation of the susceptibility of these cells to apopto-
sis (reviewed in [31]). Gene expression profiling 
has shown similar increases in some genes control-
ling elements of the NF-?B pathway in both pe-
ripheral blood mononuclear cells (PBMC) from 
MS patients and in EAE models [32]. These prop-
erties suggest a role for the NF-?B pathway in MS 
pathogenesis and, thus, potential as a therapeutic 
target in MS. 
2. NF-?B AND PATHWAYS OF ACTIVA-
TION 
 NF-?B is a ubiquitous transcription factor that 
plays an important role in controlling gene expres-
sion in inflammation, immunity, cell proliferation 
and apoptosis [33, 34]. In mammals, NF-?B com-
prises a family of five protein subunits, p50, p52, 
RelA (p65), c-Rel, and Rel-B, which share an N-
terminal 300 amino acid Rel homology domain 
that allows them to dimerize, translocate to the nu-
cleus and bind to specific DNA sequences known 
as ?B sites [31, 35] – thereby regulating the ex-
pression of a variety of genes [35-37]. Target gene 
specificity is determined by the specific NF-?B 
complexes present in different cell types, the ?B 
target site binding specificities of different NF-?B 
complexes, and the particular protein-protein in-
teractions and post-translational modifications that 
NF-?B complexes undergo in different contexts 
[38, 39]. 
 In most resting cells, hetero- or homo- dimers 
of NF-?B subunits are retained in an inactive form 
in the cytoplasm through association with any of a 
family of inhibitory proteins, known collectively 
as I?B (I?B?, I?B?, I?B?, I?B?, BCL3, p100, 
p105 and I?BL), which mask the DNA binding 
domains [40]. The I?B proteins all contain an an-
kyrin repeat of 30-33 amino acids [41, 42]. The 
specific interaction between NF-?B subunits and 
I?B is mediated through binding of the ankyrin 
repeat and the Rel-homology domain of NF-?B. 
Exposure of cells to a variety of stimuli leads to 
the rapid phosphorylation, ubiquitination, and ul-
timately proteolytic degradation of I?B, which 
frees NF-?B to translocate to the nucleus and acti-
vate gene transcription. The phosphorylation of 
I?B is achieved through the action of the I?B 
kinase (IKK) complex. 
 Extracellular stimuli that can induce NF-?B 
activation include proinflammatory cytokines, bac-
teria and fungi and their products, viruses and viral 
products, eukaryotic parasites, physiological stress 
conditions, physical and oxidative stress, environ-
mental factors, therapeutically used drugs, modi-
fied proteins, apoptotic mediators, mitogens, 
growth factors and hormones, and chemical agents 
[31, 35, 43, 44] (see http://www.nf-kb.org/induc 
ers/ for a full listing), many of which have been 
implicated in the development of autoimmune dis-
eases such as MS. Genes regulated by NF-?B in-
clude pro-inflammatory cytokines/chemokines and 
their modulators, inflammatory enzymes such as 
nitric oxide synthases and the matrix metalloprote-
inases, cell adhesion molecules, proteins involved 
in antigen presentation to T cells, acute phase pro-
teins, stress-response genes, growth factors, and 
regulators of apoptosis [31]. In addition, a range of 
genes encoding extracellular stimuli of NF-?B ac-
tivity can also be transcribed by activated NF-?B, 
resulting in rapid amplification of the NF-?B 
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pathways and perpetuation of inflammatory re-
sponses. 
 Two major NF-?B activating signal transduc-
tion pathways have been described [45], the clas-
sical and alternative pathways (Fig. 1). The classi-
cal NF-?B pathway, also called the canonical 
pathway, is initiated by pro-inflammatory cytoki-
nes such as tumor necrosis factor-? (TNF-?) bind-
ing to their specific receptor, leading to the se-
quential recruitment of various adaptors (for TNF-
? signalling these include TNF-receptor-associated 
death domain protein, receptor-interacting protein 
and TNF-receptor-associated factor 2) to the cyto-
plasmic membrane [46]. This is followed by the 
recruitment (via interactions between NEMO (NF-
?B essential modulator) and receptor-interacting 
protein) and activation of the classical IKK com-
plex, which is composed of two catalytic subunits, 
IKK? and IKK?, (as homo- or hetero-dimers) and 
a regulatory subunit known as NEMO or IKK?. 
IKK then phosphorylates two N-terminal serines 
of I?B [47], causing the ubiquitination and degra-
dation of I?Bs through the 26S proteasome path-
way [48, 49] and allowing NF-?B dimers to enter 
the nucleus, where they bind to sites in the pro-
moter regions of target DNA elements that have 
the consensus sequence GGGRNNYYCC (R = 
purine, N = any base, and Y = pyrimidine) and 
transiently activate transcription of genes encoding 
proteins involved in immune or inflammatory re-
sponses and cell growth control [50]. The classical 
pathway usually involves NF-?B heterodimers of 
p50/p65, complexed to I?B? in unstimulated cells, 
with IKK? mediating the phosphorylation-induced 
proteolysis of I?B? [51]. The NF-?B/I?B complex 
can shuttle between the cytoplasm and the nucleus 
[52], but because the export rate from nucleus to 
cytoplasm is higher than import from cytoplasm to 
nucleus, the complex is primarily cytoplasmic. 
The NF-?B/I?B complex in the nucleus cannot 
initialize gene transcription, as the DNA-binding 
domain is blocked by I?B. Classical pathway acti-
vation usually occurs within minutes of the initial 
stimulus. 
 In contrast, the alternative NF-?B pathway, also 
called the non-canonical pathway, is NEMO-
independent and is initiated by cytokines such as 
lymphotoxin ? [53], B-cell activating factor [54] 
or the CD40 ligand [55] and viruses such as Ep-
stein Barr virus [56]. Activation of the alternative 
pathway is a much slower process than activation 
of the classical pathway, taking several hours. This 
pathway is thought to operate primarily in the im-
mune system, playing a role in B-cell, T-cell and 
secondary lymphoid organ development [57]. In-
teraction of the stimuli with cell surface receptors 
leads to the activation of the NF-?B inducible 
kinase, which then phosphorylates IKK? to trigger 
the processing of p100, via interaction with the S9 
subunit of the 19S proteasome, to mature p52. The 
p52 subunit can then dimerize with RelB, p65 or 
c-Rel. Once generated, p52/RelB dimers are free 
to move to the nucleus, whereas p52/p65 or p52/c-
Rel dimers are first captured by I?Bs and then ac-
tivated through the classical pathway [57]. Re-
cently, it has been found that IKK? accelerates 
both the turnover of p65 and its removal from pro-
inflammatory gene promoters [58], suggesting that 
the alternative pathway plays a major role in reso-
lution of the early inflammatory process and to the 
onset of tolerance to self [59, 60]. Thus, cross-
regulation between the classical and alternative 
signaling pathways appears to be crucial in pro-
moting an optimally protective response that is 
balanced between inflammation and tolerance 
[58]. 
 Atypical NF-?B signaling pathways that are 
independent of IKK, but that still require the pro-
teasome, have also been described [61-64]. In 
these atypical pathways, phosphorylation of I?B? 
residues other than those N-terminal serine resi-
dues phosphorylated by IKK occurs. For example, 
UV radiation induces I?B? degradation via the 
proteasome, but the targeted serine residues are 
located within a C-terminal cluster that is recog-
nized by the p38-activated casein kinase 2. Oxida-
tive stress leads to NF-?B activation via 
phosphorylation of the N-terminal tyrosine at 
residue 42, and the Syk protein tyrosine kinase is 
required for H2O2-mediated NF-?B activation. 
 In addition, constitutive activation of NF-?B 
pathways has been described in many situations, 
such as during embryonic development, the devel-
opment of B cells, macrophages and cancer cells, 
in some cells in the CNS, and in some inflamma-
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tory and autoimmune diseases [65, 66]. I?B? ap-
pears to be a key element associated with constitu-
tive activation of NF-?B in many different types 
of cells. I?B? binds the same NF-?B dimers as 
does I?B?; however, I?B? is only degraded after 
more sustained stimulation [65]. Degradation of 
I?B? requires the phosphorylation of Ser19 and 
Ser23, whereas phosphorylation of Ser32 and 
Ser36 is required for degradation of I?B?. I?B? 
also differs from I?B? in that it has six ankyrin 
repeats where I?B? has five. The specific number 
of ankyrin repeats in I?B has been proposed to 
play an important role in determining NF-?B 
subunit binding [66]. In addition, the gene encod-
ing I?B?, but not I?B?, contains a ?B binding site, 
which allows it to be rapidly restored through NF-
?B initiated transcription and in turn bind to NF-
?B to quickly stop further activation. In contrast, 
I?B? and I?B? are synthesized constitutively and 
re-establish NF-?B inhibition with a relatively 
slow time-course. 
3. ROLE OF NF-?B IN CELLS TYPES IN-
VOLVED IN MS 
 NF-?B plays unique and distinct functions in 
different types of cells. The fine regulation of NF-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). NF-?B signal transduction pathways and potential target sites for inhibition of the pathways for treatment of MS. The 
classical pathway (on the left) is triggered by pro-inflammatory cytokines (e.g. TNF-?). Upon binding of the pro-inflammatory 
cytokine to the receptor, various adaptor proteins (TRAFs, RIP) are recruited to the membrane. Interactions between NEMO 
and RIP lead to recruitment and activation of the IKK complex. Activated IKK induces phosphorylation, ubiquitination and 
degradation of I?B-?, releasing the NF?B dimer to enter the nucleus, where it can bind with ?B sites in the gene promoter re-
gion and initiate gene transcription. In the alternative pathway (on the right), TRAF is recruited following receptor engage-
ment. This leads to activation of NIK, phosphorylation of IKK?, and phosphorylation, ubiquitination and cleavage of the C-
terminal part of NF-?B p100 to generate p52. Dimers of p52 and RelB can then translocate to the nucleus to initiate gene tran-
scription. Inhibition of NF-?B activation can be achieved at different stage in the pathways, as indicated by ? symbols. 
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?B activation depends on the type of cell, the 
stimulus applied to it, the adaptors recruited by the 
stimulus, the residues of  IKK and  I?Bs that are 
phosphorylated or otherwise post-translationally 
modified, and the composition of the NF-?B di-
mers. Much remains to be understood regarding 
the exact mechanisms of NF-?B action in many 
cell types, and how modulation of NF-?B activa-
tion as a therapeutic modality might affect the 
body as a whole. Some of the mechanisms of NF-
?B activation for cells involved in the develop-
ment of MS are discussed below. 
Lymphocytes 
 The NF-?B pathway fulfills diverse roles in the 
development, maturation, and homeostasis of lym-
phocytes, and has been extensively studied and 
recently reviewed [34, 67, 68]. Both classical and 
alternative NF-?B pathways play crucial roles in 
development of immature B and T cells and in the 
maintenance of mature lymphocytes. Both path-
ways are also required for the development of sec-
ondary lymphoid organs such as the spleen and 
lymph nodes [68]. Activation of NF-?B after rec-
ognition of antigen by the T or B cell receptors is 
critical for regulation of genes involved in pivotal 
mechanisms such as proliferation of activated 
lymphocytes, IL2 production, differentiation of Th 
cells to Th1, Th2 or Th17 phenotypes, antibody 
class switching, and survival. There is evidence 
that persistent lymphocyte NF-?B activation oc-
curs in lesions of many chronic inflammatory dis-
eases, including MS [43], which contributes to 
autocrine/par-acrine loops of inflammatory cyto-
kines and growth factors capable of maintaining 
activation of non-immune cells within the lesions. 
 Much of what is known of the role of NF-?B in 
immune cells has come from studies using condi-
tional knockout of components of the NF-?B 
pathway. B cells that lack IKK? survive poorly 
[69] and do not make strong antibody responses 
upon antigen stimulation [70]. Additionally, stud-
ies of B cells from patients with X-linked an-
hidrotic ectodermal dysplasia with hyper-IgM 
syndrome, who have deficient expression of 
NEMO, have shown that the classical NF-?B 
pathway regulates V(D)J recombination in B cells, 
which is essential to produce an Ig repertoire with 
a large range of Ag specificities. The generation of 
memory B cells and somatic hypermutation were 
also markedly deficient in these cells, confirming a 
role for NF-?B in B cell maturation [71]. 
 Deletion of IKK? in T cells has shown that 
IKK? is not absolutely required for survival of na-
ive peripheral T cells but plays a major role in the 
generation of Treg, natural killer T (NKT) cells 
and memory T cells [72, 73]. This is of interest for 
MS, where Treg are decreased in their number and 
function [27]. In contrast, T cell-specific deletion 
of NEMO or replacement of endogenous IKK? 
with a kinase-dead mutant is incompatible with 
mature T cell generation and/or persistence [72]. 
In general, pro-inflammatory T cell responses ap-
pear to be mediated through the classical NF-?B 
pathway. Much attention in MS and other auto-
immune diseases recently has focused on the role 
of the pro-inflammatory IL-17-secreting Th17 
cells. IL-17 has been shown to be a potent activa-
tor of the classical NF-?B pathway [74]. 
 There is also much interest in the role of activa-
tion of the alternative NF-?B pathway in the gen-
eration of Treg. Several receptor pairs involved in 
T cell signaling are also responsible for regulating 
T cell activation through a process of “reverse sig-
naling”, whereby there is immediate feedback to 
the antigen-presenting cells upon their initiation of 
the forward signal in the T cell. Depending on the 
type of antigen-presenting cell and the particular 
receptor pair, this can result in activation of an 
immunoregulatory pathway of tryptophan catabo-
lism, which is initiated by the enzyme indoleamine 
2,3-dioxygenase (IDO), resulting in the expression 
of anti-inflammatory cytokines such as IL-10 by 
the antigen-presenting cell and generation of Treg 
[75]. Non-canonical NF-?B activation is necessary 
for the induction of IDO in response to reverse 
signaling, possibly due to the presence of a bind-
ing site for p52/p65 dimers in the promoter of the 
gene encoding IDO [76-78]. 
Dendritic Cells 
Dendritic cells (DC) play an essential role in both 
induction of immune responses and the develop-
ment of autoimmunity. Ligation of CD40 on DC 
induces early production of inflammatory media-
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tors via canonical NF-?B signaling, as well as late 
expression of the anti-inflammatory enzyme IDO 
via the alternative pathway of NF-?B signaling 
[60]. In addition, alternative pathway NF-?B sig-
naling down-regulates pro-inflammatory cytokine 
production in DCs and selective activation of this 
pathway results in non-inflammatory DCs that 
suppress T-cell activation and promote the devel-
opment of Treg [60]. 
Macrophages 
 Macrophages are important inflammatory cells 
in the CNS during MS, and represent the most 
numerous cell type present in the active MS lesion. 
The NF-?B classical pathway can be robustly acti-
vated within macrophages by many stimuli, and 
contributes to the induction of genes responsible 
for the antigen processing and presentation abili-
ties of the macrophages [79]. Conditional knock-
out of IKK? in macrophages leads to dramatic de-
creases in the levels of IL6, IL12 and the 
chemokine CXCL1 [80, 81]. IKK?, on the other 
hand, negatively controls classical NF-?B signal-
ing in macrophages and promotes the resolution of 
inflammation [58], suggesting that the alternative 
pathway may operate in a similar manner in 
macrophages as in DC. 
CNS Cells 
 In the CNS, NF-?B subunits display a devel-
opment and spatial regulation in their expression 
(review in [82, 83]). NF-?B appears to play a 
complex role in integrating signaling between and 
within neurons and glial cells (microglia and as-
trocytes) and there is relatively high constitutive 
activity of NF-?B in brain tissue compared with 
other tissues [84], particularly in areas of high 
metabolic activity, e.g. hippocampus and cortex 
[85]. This is thought to be due, at least in part, to 
the activation of the NF-?B pathway by stimula-
tion through glutamate receptors. Traumatic or de-
generative damage to the CNS induces numerous 
signaling events that stimulate NF-?B activity in 
all cells. In neurons undergoing excitotoxic- or 
age-related degeneration, NF-?B activation has 
been proposed to have a protective, anti-apoptotic 
role [84], and inactivation of the gene encoding 
I?B? results in increased susceptibility of neurons 
to oxidative, excitotoxic and metabolic insults. In 
contrast, focal or global ischaemia activates 
p50/p65 dimers and promotes cell death [86]. 
 NF-?B activation controls microglial migration 
to sites of injury [87], where their effects can be 
either neuroprotective or destructive, depending on 
the stimulus, duration and threshold levels of the 
microglia. In normal appearing white matter, p65, 
but not c-Rel, p50 or I?B, has been found in the 
nuclei of microglia [88]. Activation of the NF-?B 
activity in microglial cells and astrocytes, such as 
occurs in MS, usually results in the production of 
proinflammatory cytokines and potentially neuro-
toxic mediators, such as reactive oxygen species 
and excitotoxins [82]. This is not unexpected, as 
microglia and astrocytes share many behaviors 
with macrophages. 
 Of particular relevance to MS is the finding that 
NF-?B, induced in oligodendrocytes by factors 
that are produced by non-activated microglia and 
which signal through a PDGF? receptor signaling 
pathway, has a pro-survival role and promotes 
maturation of oligodendrocyte progenitors [89]. 
There is conflicting evidence regarding the role of 
NF-?B activation in mature oligodendrocytes, 
with some studies showing that translocation of 
p50, p65 and c-Rel containing dimers mediates 
apoptotic cell death of mature oligodendrocytes 
[90], but others finding that NF-?B activation can 
prevent cell death. In MS the latter may be the 
case, since there is a paucity of oligodendrocyte 
apoptosis in active lesions [91]. 
4. NF-?B IN MS AND EAE 
 Several studies over the last 10 years have in-
vestigated the localization of NF-?B in MS brain 
tissue. In active MS plaques, p50, p65, c-Rel and 
I?B were all found in the nuclei of infiltrating 
macrophages, and p65 was also present in the nu-
clei of hypertrophic astrocytes [88, 91]. Activated 
p65 was also increased in the nuclei of some oli-
godendrocytes in active plaques, but not in oli-
godendrocytes in normal-appearing white matter, 
and no I?B could be detected in the nuclei of oli-
godendrocytes in any area [91]. Perivascular infil-
trating lymphocytes in active plaques were re-
ported to have c-Rel, but not p50 or p65, in the 
nuclei [88]. In addition, cDNA microarray analysis 
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of brain tissue showed that genes related to NF-?B 
are often upregulated in tissue from patients with 
MS compared to controls [92-99]; there is, how-
ever, a fair amount of variability in the individual 
reports, probably due to differences in the disease 
state and treatment history of the patients, the par-
ticular microarray platform used, and whether or 
not the tissue tested was from an area of active in-
flammation and demyelination. An excellent re-
view of these microarray studies has recently been 
published [32] and thus they will not be consid-
ered here. 
 Other studies in humans have focused on the 
activation of NF-?B in PBMC from MS patients 
and healthy controls. These results have been 
somewhat conflicting, probably reflecting the 
small numbers of patients tested, differences in 
their clinical state at the time of testing, and the 
different NF-?B subunits assessed. Flores and col-
leagues [100] tested NF-?B activation in PBMC 
from 11 healthy controls and 10 untreated RR-MS 
patients in remission and did not find any differ-
ences between the groups. In contrast, Eggert and 
colleagues [101] found elevated levels of DNA-
binding p50, but not p65, in a group consisting of 
5 patients with RR-MS, 10 with SP-MS and 5 with 
PP-MS, compared to 24 healthy controls. Two 
studies have recently used microarray technology 
to investigate differences in gene expression in 
PBMC of healthy individuals and people with MS 
[102, 103]. One of these compared levels of gene 
expression in a group of 22 RR-MS patients un-
dergoing a relapse with 20 RR-MS patients who 
were in remission [102]. They found 1,578 gene 
transcripts that significantly differentiated acute 
relapse from remission; these transcripts were en-
riched in genes relating to apoptotic-related path-
ways, including over-expression of p65 in PBMC 
from acute relapse. The other study [103] com-
pared samples from 21 healthy controls and 24 
patients with MS (mostly of the RR-MS type), and 
did not find significant upregulation of genes en-
coding NF-?B subunits, although there was in-
creased expression of the TNF receptor in MS pa-
tients compared to controls. It was not specified 
whether MS patients in this later study were in re-
lapse or remission. 
Table 2. Current Therapeutic Agents Used in MS 
 
Drug Mode of Action Effects 
Corticosteroids Immunosuppression 
Decrease duration and severity of relapses in some 
patients. No long term impact [1,178] 
Cyclophosphamide, azathioprine, 
cyclosporine, methotrexate, cladrib-
ine) 
Immunosuppression/cell cycle interrup-
tion 
Modest effects with associated toxicity 
Beta interferon (Betase-
ron/Rebif/Avonex) 
Immunomodulation 
Decreased blood-brain barrier permeabil-
ity? [148] 
Induction of Treg? [179] 
Reduce relapse rate in RR-MS. Modest effect in 
delaying disability. No effect in SP-MS or PP-MS. 
(Reviewed in [180]) 
Copaxone 
(Glatiramer acetate) 
Immunomodulation (?altered peptide 
ligand) 
Some effect on relapse rate and modest effect in 
delaying disability. No effect in SP-MS or PP-MS 
[181-184] 
Mitoxantrone (Novantrone) Cell cycle interruption 
Short term effects in RR-MS and SP-MS, but car-
diotoxicity limits use. Risk of secondary acute mye-
logenous leukemia [185-187] 
Natulizumab (Tysabri – 
anti-VLA-4 antibody) 
Blocks movement of T cells and other 
leukocytes (apart from neutrophils) into 
CNS 
Good efficacy in RR-MS in reducing relapse rate. 
Not tested in SP-MS or PP-MS. Risk of progressive 
multifocal leukoencephalopathy in patients who 
carry JC virus [188-190] 
Intravenous immunoglobulin Immunomodulation 
Limited effects in RR-MS. No effects in SP-MS 
[191,192] 
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 A large number of studies have addressed the 
role of NF-?B activation in EAE [104-131]. Ex-
trapolating findings from the EAE model to MS 
requires some caution, because data from differen-
tial gene expression studies suggest that, whereas 
EAE is an immunological disease that targets a 
healthy brain /spinal cord with very little intrinsic 
alteration of brain function, the pathogenetic proc-
esses in MS brain involve a target tissue that is 
itself functionally altered [32]. In addition, since 
EAE is usually induced by injection of myelin pro-
teins or peptides in complete Freund’s adjuvant, 
which is a potent activator of the canonical path-
way of NF-?B, the results may be skewed some-
what in favor of this pathway. Generally, it has 
been found that p65 and p50, but not c-Rel, RelB 
or p52, are the prototypic inducible NF-?B 
subunits in the CNS during EAE [113,118,124]. 
This is supported by findings from van Loo and 
colleagues [132] who showed that ablation of 
NEMO or IKK?, but not IKK?, in non-microglial 
CNS cells resulted in ablation of EAE, suggesting 
that canonical NF-?B activation in the CNS has a 
mainly pathogenic effect. In the periphery, c-Rel is 
critical for development of encephalitogenic T 
cells [114]. Many of these EAE studies have 
shown that drugs which decrease NF-?B activa-
tion can lead to protection against EAE [104, 107, 
110, 116, 120-123, 126, 128, 129, 131-135]. This 
will be discussed further below. 
5. NF-?B POLYMORPHISMS AND MS 
 The MHC class II region has been linked with 
susceptibility to MS, with carriage of HLA. 
 DRB1*1501 promoting an approximately 3- to 
4- fold relative risk in most populations [136, 
137]. The MHC region contains about 160 genes 
[138], including those encoding TNF and I?BL. 
As noted earlier, TNF-? is the prototypic cytokine 
for induction of the classical NF-?B pathway. 
TNF-? levels are increased in blood and cerebro-
spinal fluid from MS patients and in demyelinated 
plaques in the CNS. TNF-? also regulates myelin 
basic protein gene transcription through NF-?B in 
a human oligodendroglioma cell line [139].  
 
 
However, TNF polymorphisms have not been 
found to associate with susceptibility to MS [140, 
141]. 
 I?BL is related to other I?B family members, 
although it only contains two complete and one 
partial ankyrin repeats, whereas other I?B proteins 
contain 6-7 [142]; however, the ankyrin repeats in 
I?BL are sufficient for interaction with members 
of the NF?B family. The I?BL protein is most 
similar to I?B?. The gene encoding I?BL (IKBL) 
is located in the central MHC region [143] and 
contains several structural polymorphisms. A 
polymorphism at position 738 in exon 4, which 
results in an amino acid change from cysteine to 
arginine in the I?BL, has been linked with predis-
position to MS and is additionally associated with 
HLA DRB1*1501 [140, 144, 145]. It is thought 
that this polymorphism would affect phosphoryla-
tion of the I?BL, causing it to dissociate from NF-
?B. Although significantly over-represented in 
RR-MS [145], thus far there have been no studies 
to test whether NF-?B activation is altered in RR-
MS patients who carry this IKBL polymorphism. 
Polymorphisms in IKBL also influence the risk for 
development of systemic lupus erythematosus and 
Sjögren’s syndrome [146]. Since systemic lupus 
erythematosus and Sjögren’s syndrome are primar-
ily antibody-mediated disorders, this raises the 
possibility that IKBL may play a role in regulating 
B cell responses. 
 Another polymorphism implicated in PP-MS is 
an 8 base insertion in the promoter region of 
NFKBIA, the gene encoding I?B?, that is located 
on chromosome 14q13 [145]. NFKBIA is highly 
polymorphic, but the difference in frequency be-
tween healthy controls and MS patients was a sig-
nificant decrease in the frequency of the promoter 
region insertion in PP-MS compared to controls. 
The 8 base insertion in NFKBIA occurs in a region 
containing a binding site for heat shock protein, a 
molecule involved in immune regulation and in-
nate immunity. The significance of the association 
of this polymorphism with PP-MS, but not RR-MS 
or SP-MS remains to be elucidated, but suggests 
possible differences in regulation of innate immu-
nity in the different types of MS. 
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6. CURRENT THERAPEUTIC AGENTS IN 
MS AND THEIR EFFECTS ON THE NF-?B 
PATHWAY 
 Current therapeutic agents for MS mainly target 
autoimmune and inflammatory aspects of the dis-
ease and thus are designed using strategies of im-
munosuppression, immunomodulation, and cell 
cycle interruption. Commonly used agents and 
their mode(s) of action are summarized in Table 2. 
Most of these pharmacological agents are only 
used for treatment of RR-MS, and while some 
have shown efficacy in lessening the relapse rate 
in RR-MS and time to progression, they cannot 
cure MS and there are few treatments available for 
PP-MS and SP-MS. Some of these agents are now 
thought to act by mechanisms that regulate the 
NF-?B pathway. 
 Beta interferon (IFN-?) is one of the most 
commonly used drugs in the treatment of MS. It 
has been proposed that IFN-? works by shifting 
the immune response in MS from a pro-
inflammatory Th1 to anti-inflammatory Th2 type, 
and that inhibition of NF-?B activation is involved 
in this process [120, 147]. However, other studies 
suggest that IFN-? acts in a more complex way, 
actually increasing the pro-inflammatory re-
sponses in PBMC from people with MS [148], 
pointing to activation of NF-?B pathways. Treat-
ment of human primary microglia cell cultures 
with IFN-? induces NF-?B inhibitor degradation 
and NF-?B activation in these cells, resulting in 
increased levels of production of chemokines such 
as RANTES and MIP-1? [149]. Activation of NF-
?B induced by IFN-? is modulated by a protein, 
p202a, which belongs to the interferon-inducible 
p200 family and which inhibits sequence-specific 
binding to DNA [150]. Interestingly, there appear 
to be differences in response to IFN-? in females 
and males; it has been speculated that this might 
be due to the effects of the hormone estradiol on 
basal levels of NF-?B activation [151]. 
 Glucocorticoids such as methylprednisolone, 
which is used for treatment of acute exacerbations 
in MS, act by binding to a cytosolic glucocorticoid 
receptor, which is subsequently activated and 
translocated to the nucleus. Once in the nucleus, 
the glucocorticoid receptor either binds to DNA 
and switches on the expression of anti-
inflammatory genes or acts indirectly to repress 
the activity of a number of distinct signaling path-
ways such as NF-?B [152]. In one study, pulse 
therapy with methylprednisolone in MS patients 
decreased the level of activated p65 subunits in 
PBMC, leading to reduced levels of transcription-
ally active pro-inflammatory NF-?B [101]. Some 
of the other immunosuppressive drugs that are 
less-frequently used in the treatment of MS, such 
as azathioprine, also suppress NF-?B indirectly. In 
human CD4
+
 T cells, azathioprine inhibits binding 
of a protein known as Rac1 to GTP. This sup-
presses activation of NF-?B and other genes by 
Rac1, and leads to induction of T cell apoptosis 
[153]. 
 The mechanism of action of glatiramer acetate 
is not certain, and several different proposals have 
been put forward, including that it acts in a similar 
manner to altered peptide ligands to modulate the 
T cell response by acting as a partial agonist. 
However, in one study, treatment of a human as-
trocyte cell line with glatiramer acetate led to de-
creased activation of NF-?B and reduced produc-
tion of the chemokine RANTES [154], suggesting 
that it may exert indirect effects on the NF-?B 
pathway. 
7. EXPERIMENTAL STUDIES ON NF-?B 
BLOCKERS FOR TREATMENT OF MS 
 Targeting NF-?B is an attractive therapeutic 
option for RR-MS, where inflammatory CNS infil-
tration correlates closely to relapses of the disease. 
Several strategies will need to be considered for 
inhibiting NF-?B activation in MS, in order to 
control the level of suppression. Generally, block-
ing early steps in the activation pathway will lead 
to a more non-specific type of suppression. Sites to 
target could include cell-surface receptors up-
stream of the NF-?B pathway, signal transduction 
that activates IKK, I?B degradation, NF-?B trans-
location, and interfering with the binding of NF-
?B to DNA. Hundreds of molecules active at one 
or more of these sites have been identified [48]. A 
selection of molecules active at different steps in 
the NF-?B pathway (see Fig. 1) and that have been 
investigated in EAE models are described below. 
546      CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6 Yan and Greer 
 Most EAE studies show that activation of NF-
?B occurs via the canonical pathway, and strate-
gies that block binding of pro-inflammatory cyto-
kines to their receptors, such as anti-TNF? anti-
bodies and soluble TNF receptors, have been suc-
cessfully trialed in EAE [155, 156]. While show-
ing promise in EAE, anti-TNF? antibody trials in 
MS patients had the opposite effect and actually 
appeared to worsen the disease [157, 158]. 
 Recently, much attention has been given to the 
use of the curcumin, a major constituent of the 
spice turmeric, in the treatment of a wide variety 
of diseases, including cancer, infection, and auto-
immune disease. Curcumin appears to act by in-
hibiting activation of NIK, thereby blocking the 
non-canonical NF-?B pathway [159]. Treatment 
with curcumin every other day reportedly reduces 
the incidence of disease and mean clinical scores 
of mice that have been immunized to induce EAE 
[160]. 
 Further down the NF-?B pathway, several stud-
ies have investigated molecules that inhibit activa-
tion of the IKK complex for their effects in EAE. 
Peptides of the NF-?B essential modifier-binding 
domain of IKK? or IKK? have been used to spe-
cifically decrease NF-?B activation, without af-
fecting basal NF-?B activity, and were strongly 
protective against the induction of EAE in mice 
[107]. In another study, the IKK? inhibitory com-
pound PS-1145 reduced neuroantigen-specific pro-
liferation and cytokine production in vitro and di-
minished clinical signs of EAE in vivo [161]. 
 Utilizing agents that prevent the degradation of 
I?B, Moreno and colleagues [122] found that 
methylthioadenosine prevented acute EAE and 
reversed chronic EAE by preventing I?B? degra-
dation. In another study, Aktas and colleagues 
[104] used a component of green tea that blocks 
the catalytic activities of the 20S/26S proteasome 
complex, leading to the accumulation of I?B? and 
inhibition of NF-?B activation, to protect from re-
lapses of EAE. Moreover, this molecule protected 
against injury induced by N-methyl-D-aspartate or 
TRAIL in living brain tissue and directly blocked  
 
 
the formation of neurotoxic reactive oxygen spe-
cies in neurons. Vanderlugt and colleagues [162] 
showed that administration of the proteasome in-
hibitor PS-519 during the remission phase of EAE, 
following acute clinical disease, significantly re-
duced the incidence of clinical relapses, CNS 
histopathology, and T cell responses to both the 
initiating and relapse-associated neuroantigen epi-
topes. These authors found that continuous ad-
ministration of PS-519 was required to prevent 
disease relapse: drug withdrawal led to recovery of 
T cell function and onset of disease relapses within 
10-14 days. 
 Thymoquinone (black cumin/Roman coriander) 
has been reported to inhibit the activation of NF-
?B specifically by suppressing the direct binding 
of nuclear p65 to DNA [163]. Thymoquinone, ad-
ministered after the appearance of clinical signs in 
a rat model of EAE, prevented perivascular cuff-
ing and infiltration of mononuclear cells into the 
brain and spinal cord and ameliorated clinical 
signs of disease [121]. 
 Estrogens represent another potential treatment 
of MS that is thought to rely on inhibition of NF-
?B activation. It is well known that many MS pa-
tients have a reduced frequency of relapses during 
pregnancy [164-167], due at least in part to altered 
levels of sex hormones such as estriol, estradiol 
and progesterone. Studies looking at the effects of 
administration of estriol point to inhibition of NF-
?B as regulating T cell transmigration into the 
CNS and cytokine production [168]. The effects of 
estrogens during pregnancy may be mediated via 
induction of IDO in dendritic cells [169]. Given 
that IDO is thought to be a major regulator of the 
NF-?B pathway, it is likely that estrogens would 
have down-regulatory effects on immune cells, 
although their effects on cells of the CNS remain 
to be determined. 
 One caveat in studies on the effects of NF-?B 
inhibitors in EAE is that none of them have ad-
dressed possible changes in measures such as oli-
godendrocyte or neuronal cell apoptosis. These 
parameters need to be assessed in order to deter-
mine if positive effects of the inhibitors outweigh 
potentially damaging effects. 
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8. TARGETING NF-?B SIGNALING PATH-
WAY AS A THERAPEUTIC STRATEGY IN 
THE TREATMENT OF RELAPSING-
REMITTING AND PROGRESSIVE MS 
 The therapeutic efficacy of conventional MS 
drugs is limited by the deleterious effects of global 
immunosuppression. In this context NF-?B inhibi-
tors may represent an alternate therapeutic ap-
proach for MS; however, given the broad in-
volvement of NF-?B in regulating cellular proc-
esses, prolonged systemic inhibition of NF-?B 
might have unwanted side-effects. Even so, there 
may well be a place for modulation of NF-?B ac-
tivity at different phases or stages of MS. For RR-
MS, short-term treatment with inhibitors that block 
the classical NF-?B pathway at times of disease 
activity are predicted to dampen the inflammatory 
response, particularly if used in combination with 
glucocorticoids or other molecules that induce the 
generation of Treg. During RR-MS, induction of 
NF-?B activity in neurons and oligodendrocytes 
may have a beneficial effect in protecting against 
apoptosis of these cells, and thus strategies that 
target NF-?B inhibitors to immune-related cells 
might have distinct advantages. This could poten-
tially be done either by gene delivery of NF-?B 
inhibitors, or by using inhibitors that are not CNS 
penetrant. Considerable effort is currently under-
way to develop potent and selective NF-?B path-
way inhibitors. Some of the potential effects of 
inhibiting the NF-?B pathway in different cells 
involved in MS are summarized in Table 3. 
 As noted earlier, there are currently few thera-
pies available for treatment of progressive MS. It 
is unlikely that treatments that rely solely on im-
munosuppression or immunomodulation of T cell 
responses will have a strong impact on this phase 
of disease, as not only does there appear to be an 
inability to switch off the inflammatory response, 
but axonal and neuronal degeneration appear to 
play an at least equivalent role in MS progression. 
Strategies for progressive MS may therefore need 
to target several components of the NF-?B path-
way in different ways in different types of cells. 
There is chronic activation of macrophages, mi-
croglia, and other inflammatory cells in the CNS, 
which could potentially be related to persistent ac-
tivation of NF-?B through I?B?, as opposed to 
transient activation through I?B? [65]. Thus, in-
hibiting phosphorylation of I?B? in macrophages 
may provide one arm of the treatment. It addition, 
novel I?B’s, such as I?BL, may be related to the 
development of certain types of MS [145]. While 
little is currently known of I?BL, it is likely that 
the phosphorylation of this molecule will differ 
slightly from other I?B’s, thus allowing one to tar-
get specific kinases in order to inhibit this mole-
cule. Differences in the promoter region of the 
gene encoding I?B? in PP-MS patients, compared 
to other types of MS, suggest that the innate im-
mune response may be aberrantly regulated in PP-
MS. Therapeutic strategies targeting I?B? may 
therefore be beneficial in PP-MS. In progressive 
MS, it may also be efficacious to actually activate, 
rather than inhibit, the NF-?B pathway in some 
circumstances. For example, chronic inflammation 
might be cleared through the action of Treg, which 
could be induced through stimulation of the alter-
native pathway in antigen presenting cells. Finally, 
targeted activation of NF-?B pathways in neurons 
and oligodendrocyte precursors may protect those 
cells from degeneration. Conceivably, this could 
be achieved by administering trophic factors that 
activate NF-?B signaling, or through induction of 
a mild metabolic stress response, such as dietary 
restriction [82, 170]. 
 We suggest that the main considerations for the 
type of NF-?B therapy to be used in particular pa-
tients will relate to the features of that individual’s 
MS, and that this will not be a “one type fits all” 
therapeutic option. 
9. CONCLUSIONS 
 The NF-?B pathway plays critical roles not 
only in the normal functioning of both the immune 
system and the nervous system, but also in devel-
opment of and protection against disease in these 
systems. Modulation of NF-?B as a means of con-
trolling MS will require further knowledge regard-
ing the specific molecular interactions leading to 
activation of pro-inflammatory responses during 
the course of different types and phases of MS. 
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Studies in the EAE model, while informative, will 
need to be supplemented with additional informa-
tion obtained from tissues of patients with MS. In 
particular, it will be important to determine the 
pathways leading to NF-?B activation in the CNS 
during attacks of disease and recovery phases, to 
identify patterns of activation correlating with the 
clinical course and features of disease. It will also 
be essential to develop a more thorough under-
standing of the role of NF-?B in nervous system 
health and disease: the highly differentiated cell 
types and subtypes in the CNS and their interde-
pendency on one another create a particularly chal-
lenging landscape for investigators in determining 
such parameters as the subunits activated in differ-
ent cell types, the target sequence preferences of 
the subunits, and the outcomes that they induce in 
individual cells. 
ABBREVIATIONS 
BCL  = B-cell leukaemia 
CNS  = Central nervous system 
CXCL1  = Chemokine (C-X-C motif) ligand 1 
DC  = Dendritic cells 
EAE  = Experimental autoimmune  
   encephalomyelitis 
GTP  = Guanosine triphosphate 
H2O2  = Hydrogen peroxide 
HLA  = Human Leukocyte Antigen 
IDO  = indoleamine 2,3-dioxygenase 
IFN-?  = Beta interferon 
I?B  = Inhibitor of NF-?B 
I?BL  = Inhibitor of ?B-like 
IKK  = I? kinase complex 
IKK?  = Alfa subunit of the IKK complex 
IKK?  = Beta subunit of the IKK complex 
IL-17  = Interleukin-17 
MHC  = Major histocompatibility complex 
MIP-1?  = Macrophage inflammatory protein- 
   1? 
MS  = Multiple sclerosis 
NEMO  = NF-?B Essential Modulator 
NF-?B  = Nuclear factor-?B 
Table 3. Putative Effects of Inhibition of NF-?B in Different Types of Cells Involved in MS 
 
Cell Type Benefit Harm 
T lymphocyte 
? activation 
? cytokine expression 
? apoptosis susceptibility 
Generalized immunosuppression 
B lymphocyte ? antibody production Generalized immunosuppression 
Monocytes/ macrophages ? cytokine expression ? development of monocytes to macrophages 
Microglia 
? accumulation in lesion 
? cytokine expression ? ? protective effects 
Astrocytes 
? cytokine expression 
? accumulation in lesion and scar formation  
Neurons ? ? cell death 
? susceptibility to oxidative, excitotoxic and metabolic 
insults 
? apoptosis susceptibility 
? MHC class I expression  
Oligodendrocytes  ? ? cell death ? apoptosis susceptibility  
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NIK  = NF-?B Inducing Kinase 
NKT cell = Natural killer T cell 
PBMC  = Peripheral Blood Mononuclear Cell 
PP-MS  = Primary progressive MS 
RANTES  = Regulated upon Activation, Normal  
   T-cell Expressed and Secreted 
RR-MS  = Relapsing–remitting MS 
SP-MS  = Secondary progressive MS 
Syk  = Spleen tyrosine kinase 
Th1  = T helper 1 
Th17  = T helper 17 
Th2  = T helper 2 
TNF-?  = Tumor necrosis factor-? 
Treg  = Regulatory T cells 
REFERENCES 
[1] Noseworthy, J.H.; Lucchinetti, C.; Rodriguez, M.; 
Weinshenker, B.G. Multiple sclerosis. N. Engl. J. 
Med., 2000, 343, 938-52. 
[2] Dyment, D.A.; Ebers, G.C.; Sadovnick, A.D. Genet-
ics of multiple sclerosis. Lancet Neurol., 2004, 3, 
104-10. 
[3] Weiner, H.L. A shift from adaptive to innate immu-
nity: a potential mechanism of disease progression in 
multiple sclerosis. J. Neurol., 2008, 255 (Suppl 1), 3-
11. 
[4] Hafler, D.A. Multiple sclerosis. J. Clin. Invest., 2004, 
113, 788-94. 
[5] Vukusic, S.; Confavreux, C. Primary and secondary 
progressive multiple sclerosis. J. Neurol. Sci., 2003, 
206, 153-5. 
[6] Lublin, F.D.; Reingold, S.C. Defining the clinical 
course of multiple sclerosis: results of an international 
survey. National Multiple Sclerosis Society (USA) 
Advisory Committee on Clinical Trials of New 
Agents in Multiple Sclerosis. Neurology, 1996, 46, 
907-11. 
[7] Confavreux, C.; Aimard, G.; Devic, M. Course and 
prognosis of multiple sclerosis assessed by the com-
puterized data processing of 349 patients. Brain, 
1980, 103, 281-300. 
[8] Trapp, B.D.; Nave, K.A. Multiple sclerosis: an im-
mune or neurodegenerative disorder? Ann. Rev. Neu-
rosci., 2008, 31, 247-69. 
[9] Martinelli, V.; Rodegher, M.; Moiola, L.; Comi, G. 
Late onset multiple sclerosis: clinical characteristics, 
prognostic factors and differential diagnosis. Neurol. 
Sci., 2004, 25 (Suppl 4), S350-55. 
[10] Thompson, A.J.; Kermode, A.G.; Wicks, D.; 
MacManus, D.G.; Kendall, B.E.; Kingsley, D.P.; 
McDonald, W.I. Major differences in the dynamics of 
primary and secondary progressive multiple sclerosis. 
Ann. Neurol., 1991, 29, 53-62. 
[11] Thompson, A.J.; Polman, C.H.; Miller, D.H.; 
McDonald, W.I.; Brochet, B.; Filippi, M.M.X.; De 
Sa, J. Primary progressive multiple sclerosis. Brain, 
1997, 120, 1085-96. 
[12] Zaffaroni, M.; Ghezzi, A. The prognostic value of 
age, gender, pregnancy and endocrine factors in mul-
tiple sclerosis. Neurol. Sci., 2000, 21 (Suppl 2), S857-
60. 
[13] Gayou, A.; Brochet, B.; Dousset, V.J. Transitional 
progressive multiple sclerosis: a clinical and imaging 
study. Neurol. Neurosurg. Psychiatry, 1997, 63, 396-
8. 
[14] Foong, J.; Rozewicz, L.; Chong, W.K.; Thompson, 
A.J.; Miller, D.H.; Ron, M.A. A comparison of neu-
ropsychological deficits in primary and secondary 
progressive multiple sclerosis. J. Neurol., 2000, 247, 
97-101. 
[15] Pender, M.P.; Greer, J.M. Immunology of multiple 
sclerosis. Curr. Allergy Asthma Rep., 2007, 7, 285-92. 
[16] Confavreux, C.; Vukusic, S. Natural history of multi-
ple sclerosis: a unifying concept. Brain, 2006, 129, 
606-16. 
[17] Tullman, M.J.; Oshinsky, R.J.; Lublin, F.D.; Cutter, 
G.R. Clinical characteristics of progressive relapsing 
multiple sclerosis. Mult. Scler., 2004, 10, 451-54. 
[18] Pender, M.P.; Csurhes, P.A.; Greer, J.M.; Mowat, 
P.D.; Henderson, R.D.; Cameron, K.D.; Purdie, D.M.; 
McCombe, P.A.; Good, M.F. Surges of increased T 
cell reactivity to an encephalitogenic region of myelin 
proteolipid protein occur more often in patients with 
multiple sclerosis than in healthy subjects. J. Immu-
nol., 2000, 165, 5322-31. 
[19] Greer, J.M.; Csurhes, P.A.; Muller, D.M.; Pender, 
M.P. Correlation of blood T cell and antibody reactiv-
ity to myelin proteins with HLA type and lesion lo-
calization in multiple sclerosis. J. Immunol., 2008, 
180, 6402-10. 
[20] Das, M.P.; Nicholson, L.B.; Greer, J.M.; Kuchroo, 
V.K. Autopathogenic T helper cell type 1 (Th1) and 
protective Th2 clones differ in their recognition of the 
autoantigenic peptide of myelin proteolipid protein. J. 
Exp. Med., 1997, 186, 867-76. 
[21] Kroenke, M.A.; Carlson, T.J.; Andjelkovic, A.V.; 
Segal, B.M. IL-12- and IL-23-modulated T cells in-
duce distinct types of EAE based on histology, CNS 
chemokine profile, and response to cytokine inhibi-
tion. J. Exp. Med., 2008, 205, 1535-41. 
550      CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6 Yan and Greer 
[22] Kebir, H.; Kreymborg, K.; Ifergan, I.; Dodelet-
Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; 
Arbour, N.; Becher, B.; Prat, A. Human TH17 lym-
phocytes promote blood-brain barrier disruption and 
central nervous system inflammation. Nat. Med., 
2007, 13, 1173-75. 
[23] Stromnes, I.M.; Cerretti, L.M.; Liggitt, D.; Harris, 
R.A.; Goverman, J.M. Differential regulation of cen-
tral nervous system autoimmunity by T(H)1 and 
T(H)17 cells. Nat. Med., 2008, 14, 337-42. 
[24] McCandless, E.E.; Klein, R.S. Molecular targets for 
disrupting leukocyte trafficking during multiple scle-
rosis. Exp. Rev. Mol. Med., 2007, 9, 1-19. 
[25] Crawford, M.P.; Yan, S.X.; Ortega, S.B.; Mehta, 
R.S.; Hewitt, R.E.; Price, D.A.; Stastny, P.; Douek, 
D.C.; Koup, R.A.; Racke, M.K.; Karandikar, N.J. 
High prevalence of autoreactive, neuroantigen-
specific CD8+ T cells in multiple sclerosis revealed 
by novel flow cytometric assay. Blood, 2004, 103, 
4222-31. 
[26] Berthelot, L.; Laplaud, D.-A.; Pettré, S.; Ballet, C.; 
Michel, L.; Hillion, S.; Braudeau, C.; Connan, F.; Le-
frère, F.; Wiertlewski, S.; Guillet, J.-G.; Brouard, S.; 
Choppin, J.; Soulillou, J.-P. Blood CD8+ T cell re-
sponses against myelin determinants in multiple scle-
rosis and healthy individuals. Eur. J. Immunol., 2008, 
38, 1889-99. 
[27] Zozulya, A.L.; Wiendl, H. The role of regulatory T 
cells in multiple sclerosis. Nat. Clin. Pract. Neurol., 
2008, 4, 384-98. 
[28] Haas, J.; Hug, A.; Viehover, A.; Fritzsching, B.; Falk, 
C.S.; Filser, A.; Vetter, T.; Milkova, L.; Korporal, M.; 
Fritz, B.; Storch-Hagenlocher, B.; Krammer, P.H.; 
Suri-Payer, E.; Wildemann, B. Reduced suppressive 
effect of CD4+CD25high regulatory T cells on the T 
cell immune response against myelin oligodendrocyte 
glycoprotein in patients with multiple sclerosis. Eur. 
J. Immunol., 2005, 35, 3343-52. 
[29] Feger, U.; Luther, C.; Poeschel, S.; Melms, A.; 
Tolosa, E.; Wiendl, H. Increased frequency of CD4+ 
CD25+ regulatory T cells in the cerebrospinal fluid 
but not in the blood of multiple sclerosis patients. 
Clin. Exp. Immunol., 2007, 147, 412-18. 
[30] Vyshkina, T.; Kalman, B. Autoantibodies and neuro-
degeneration in multiple sclerosis. Lab. Invest., 2008, 
88, 796-807. 
[31] Baeuerle, P.A.; Henkel, T. Function and activation of 
NF-kappa B in the immune system. Ann. Rev. Immu-
nol., 1994, 12, 141-79. 
[32] Comabella, M.; Martin, R. Genomics in multiple scle-
rosis--current state and future directions. J. Neuroim-
munol., 2007, 187, 1-8. 
[33] Li, Q.; Verma, I.M. NF-kappaB regulation in the im-
mune system. Nat. Rev. Immunol., 2002, 2, 725-34. 
[34] Karin, M.; Greten, F.R. NF-kappaB: linking inflam-
mation and immunity to cancer development and pro-
gression. Nat. Rev. Immunol., 2005, 5, 749-59. 
[35] Siebenlist, U.; Franzoso, G.; Brown, K. Structure, 
regulation and function of NF-kappa B. Ann. Rev. 
Cell Biol., 1994, 10, 405-55. 
[36] Baeuerle, P.A.; Baltimore, D. NF-kappa B: ten years 
after. Cell, 1996, 87, 13-20. 
[37] Karin, M.; Ben-Neriah, Y. Phosphorylation meets 
ubiquitination: the control of NF-[kappa] B activity. 
Ann. Rev. Immunol., 2000, 18, 621-63. 
[38] Perkins, N.D. Post-translational modifications regu-
lating the activity and function of the nuclear factor 
kappa B pathway. Oncogene, 2006, 25, 6717-30. 
[39] Hoffmann, A.; Natoli, G.; Ghosh, G. Transcriptional 
regulation via the NF-kappaB signaling module. On-
cogene, 2006, 25, 6706-16. 
[40] Whiteside, S.T.; Israel, A. I kappa B proteins: struc-
ture, function and regulation. Semin. Cancer Biol., 
1997, 8, 75-82. 
[41] Yamazaki, S.; Muta, T.; Takeshige, K. A novel Ikap-
paB protein, IkappaB-zeta, induced by proinflamma-
tory stimuli, negatively regulates nuclear factor-
kappaB in the nuclei. J. Biol. Chem., 2001, 276, 
27657-62. 
[42] Yamamoto, Y.; Gaynor, R.B. IkappaB kinases: key 
regulators of the NF-kappaB pathway. Trends Bio-
chem. Sci., 2004, 29, 72-79. 
[43] Barnes, P.J.; Karin, M. Nuclear factor-kappaB: a piv-
otal transcription factor in chronic inflammatory dis-
eases. N. Engl. J. Med., 1997, 336, 1066-71. 
[44] Ghosh, S.; May, M.J.; Kopp, E.B. NF-kappa B and 
Rel proteins: evolutionarily conserved mediators of 
immune responses. Ann. Rev. Immunol., 1998, 16, 
225-60. 
[45] Viatour, P.; Merville, M.P.; Bours, V. Phosphoryla-
tion of NF-kappaB and IkappaB proteins: implica-
tions in cancer and inflammation. Trends Biochem. 
Sci., 2005, 30, 43-52. 
[46] Hsu, H.; Xiong, J.; Goeddel, D.V. The TNF receptor 
1-associated protein TRADD signals cell death and 
NF-kappa B activation. Cell, 1995, 81, 495-504. 
[47] Brown, K.; Gerstberger, S.; Carlson, L.; Franzoso, G.; 
Siebenlist, U. Control of I kappa B-alpha proteolysis 
by site-specific, signal-induced phosphorylation. 
Science, 1995, 267, 1485-88. 
[48] Gilmore, T.D.; Herscovitch, M. Inhibitors of NF-
kappaB signaling: 785 and counting. Oncogene, 
2006, 25, 6887-99. 
[49] Baldwin, A.S., Jr. The NF-kappa B and I kappa B 
proteins: new discoveries and insights. Ann. Rev. Im-
munol., 1996, 14, 649-83. 
NF-?B, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6     551 
[50] Pahl, H.L. Activators and target genes of Rel/NF-
kappaB transcription factors. Oncogene, 1999, 18, 
6853-66. 
[51] Bonizzi, G.; Karin, M. The two NF-kappaB activation 
pathways and their role in innate and adaptive immu-
nity. Trends Immunol., 2004, 25, 280-88. 
[52] Birbach, A.; Gold, P.; Binder, B.R.; Hofer, E.; de 
Martin, R.; Schmid, J.A. Signaling molecules of the 
NF-kappa B pathway shuttle constitutively between 
cytoplasm and nucleus. J. Biol. Chem., 2002, 277, 
10842-51. 
[53] Dejardin, E.; Droin, N.M.; Delhase, M.; Haas, E.; 
Cao, Y.; Makris, C.; Li, Z.W.; Karin, M.; Ware, C.F.; 
Green, D.R. The lymphotoxin-beta receptor induces 
different patterns of gene expression via two NF-
kappaB pathways. Immunity, 2002, 17, 525-35. 
[54] Claudio, E.; Brown, K.; Park, S.; Wang, H.; Sieben-
list, U. BAFF-induced NEMO-independent process-
ing of NF-kappa B2 in maturing B cells. Nat. Immu-
nol., 2002, 3, 958-65. 
[55] Coope, H.J.; Atkinson, P.G.; Huhse, B.; Belich, M.; 
Janzen, J.; Holman, M.J.; Klaus, G.G.; Johnston, 
L.H.; Ley, S.C. CD40 regulates the processing of NF-
kappaB2 p100 to p52. EMBO J., 2002, 21, 5375-85. 
[56] Eliopoulos, A.G.; Caamano, J.H.; Flavell, J.; Rey-
nolds, G.M.; Murray, P.G.; Poyet, J.L.; Young, L.S. 
Epstein-Barr virus-encoded latent infection membra-
ne protein 1 regulates the processing of p100 NF-
kappaB2 to p52 via an IKKgamma/NEMO-
independent signalling pathway. Oncogene, 2003, 22, 
7557-69. 
[57] Dejardin, E. The alternative NF-kappaB pathway 
from biochemistry to biology: pitfalls and promises 
for future drug development. Biochem. Pharmacol., 
2006, 72, 1161-79. 
[58] Lawrence, T.; Bebien, M.; Liu, G.Y.; Nizet, V.; 
Karin, M. IKKalpha limits macrophage NF-kappaB 
activation and contributes to the resolution of in-
flammation. Nature, 2005, 434, 1138-43. 
[59] Kinoshita, D.; Hirota, F.; Kaisho, T.; Kasai, M.; 
Izumi, K.; Bando, Y.; Mouri, Y.; Matsushima, A.; 
Niki, S.; Han, H.; Oshikawa, K.; Kuroda, N.; Mae-
gawa, M.; Irahara, M.; Takeda, K.; Akira, S.; Matsu-
moto, M. Essential role of IkappaB kinase alpha in 
thymic organogenesis required for the establishment 
of self-tolerance. J. Immunol., 2006, 176, 3995-4002. 
[60] Tas, S.W.; Vervoordeldonk, M.J.; Hajji, N.; Schuite-
maker, J.H.; van der Sluijs, K.F.; May, M.J.; Ghosh, 
S.; Kapsenberg, M.L.; Tak, P.P.; de Jong, E.C. Non-
canonical NF-kappaB signaling in dendritic cells is 
required for indoleamine 2,3-dioxygenase (IDO) in-
duction and immune regulation. Blood, 2007, 110, 
1540-49. 
[61] Tergaonkar, V.; Bottero, V.; Ikawa, M.; Li, Q.; 
Verma, I.M. IkappaB kinase-independent IkappaBal-
pha degradation pathway: functional NF-kappaB ac-
tivity and implications for cancer therapy. Mol. Cell. 
Biol., 2003, 23, 8070-83. 
[62] Imbert, V.; Rupec, R.A.; Livolsi, A.; Pahl, H.L.; 
Traenckner, E.B.; Mueller-Dieckmann, C.; Farahifar, 
D.; Rossi, B.; Auberger, P.; Baeuerle, P.A.; Peyron, 
J.F. Tyrosine phosphorylation of I kappa B-alpha ac-
tivates NF-kappa B without proteolytic degradation of 
I kappa B-alpha. Cell, 1996, 86, 787-98. 
[63] Kato, T., Jr.; Delhase, M.; Hoffmann, A.; Karin, M. 
CK2 Is a C-Terminal IkappaB Kinase Responsible for 
NF-kappaB Activation during the UV Response. Mol. 
Cell, 2003, 12, 829-39. 
[64] Takada, Y.; Mukhopadhyay, A.; Kundu, G.C.; Maha-
beleshwar, G.H.; Singh, S.; Aggarwal, B.B. Hydrogen 
peroxide activates NF-kappa B through tyrosine 
phosphorylation of I kappa B alpha and serine phos-
phorylation of p65: evidence for the involvement of I 
kappa B alpha kinase and Syk protein-tyrosine kinase. 
J. Biol. Chem., 2003, 278, 24233-41. 
[65] Thompson, J.E.; Phillips, R.J.; Erdjument-Bromage, 
H.; Tempst, P.; Ghosh, S. I kappa B-beta regulates the 
persistent response in a biphasic activation of NF-
kappa B. Cell, 1995, 80, 573-82. 
[66] Tergaonkar, V.; Correa, R.G.; Ikawa, M.; Verma, 
I.M. Distinct roles of IkappaB proteins in regulating 
constitutive NF-kappaB activity. Nat. Cell Biol., 
2005, 7, 921-23. 
[67] Siebenlist, U.; Brown, K.; Claudio, E. Control of 
lymphocyte development by nuclear factor-kappaB. 
Nat. Rev. Immunol., 2005, 5, 435-45. 
[68] Hayden, M.S.; West, A.P.; Ghosh, S. NF-kappaB and 
the immune response. Oncogene, 2006, 25, 6758-80. 
[69] Pasparakis, M.; Schmidt-Supprian, M.; Rajewsky, K. 
IkappaB kinase signaling is essential for maintenance 
of mature B cells. J. Exp. Med., 2002, 196, 743-52. 
[70] Li, Z.-W.; Omori, S.A.; Labuda, T.; Karin, M.; Rick-
ert, R.C. IKK beta is required for peripheral B cell 
survival and proliferation. J. Immunol., 2003, 170, 
4630-37. 
[71] Souto-Carneiro, M.M.; Fritsch, R.; Sepulveda, N.; 
Lagareiro, M.J.; Morgado, N.; Longo, N.S.; Lipsky, 
P.E. The NF-kappaB canonical pathway is involved 
in the control of the exonucleolytic processing of cod-
ing ends during V(D)J recombination. J. Immunol., 
2008, 180, 1040-49. 
[72] Schmidt-Supprian, M.; Courtois, G.; Tian, J.; Coyle, 
A.J.; Israel, A.; Rajewsky, K.; Pasparakis, M. Mature 
T cells depend on signaling through the IKK com-
plex. Immunity, 2003, 19, 377-89. 
[73] Schmidt-Supprian, M.; Tian, J.; Grant, E.P.; Pas-
parakis, M.; Maehr, R.; Ovaa, H.; Ploegh, H.L.; 
Coyle, A.J.; Rajewsky, K. Differential dependence of 
CD4+CD25+ regulatory and natural killer-like T cells 
552      CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6 Yan and Greer 
on signals leading to NF-kappaB activation. Proc. 
Natl. Acad. Sci. USA, 2004, 101, 4566-71. 
[74] Shen, F.; Gaffen, S.L. Structure-function relationships 
in the IL-17 receptor: implications for signal trans-
duction and therapy. Cytokine, 2008, 41, 92-104. 
[75] Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; 
Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, 
P.; Antonia, S.J.; Burgess, R.; Slingluff, C.L., Jr.; 
Mellor, A.L. Potential regulatory function of human 
dendritic cells expressing indoleamine 2,3-
dioxygenase. Science, 2002, 297, 1867-70. 
[76] Grohmann, U.; Volpi, C.; Fallarino, F.; Bozza, S.; 
Bianchi, R.; Vacca, C.; Orabona, C.; Belladonna, 
M.L.; Ayroldi, E.; Nocentini, G.; Boon, L.; Bistoni, 
F.; Fioretti, M.C.; Romani, L.; Riccardi, C.; Puccetti, 
P. Links Reverse signaling through GITR ligand en-
ables dexamethasone to activate IDO in allergy. Nat. 
Med., 2007, 13, 579-86. 
[77] Puccetti, P.; Fallarino, F. Generation of T cell regula-
tory activity by plasmacytoid dendritic cells and tryp-
tophan catabolism. Blood Cells. Mol. Dis., 2008, 40, 
101-05. 
[78] Puccetti, P.; Grohmann, U. IDO and regulatory T 
cells: a role for reverse signalling and non-canonical 
NF-kappaB activation. Nat. Rev. Immunol., 2007, 7, 
817-23. 
[79] Groesdonk, H.V.; Schlottmann, S.; Richter, F.; Geor-
gieff, M.; Senftleben, U. Escherichia coli prevents 
phagocytosis-induced death of macrophages via clas-
sical NF-kappaB signaling, a link to T-cell activation. 
Infect. Immun., 2006, 74, 5989-6000. 
[80] Chu, W.; Gong, X.; Li, Z.; Takabayashi, K.; Ouyang, 
H.; Chen, Y.; Lois, A.; Chen, D.J.; Li, G.C.; Karin, 
M.; Raz, E. DNA-PKcs is required for activation of 
innate immunity by immunostimulatory DNA. Cell, 
2000, 103, 909-18. 
[81] Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; 
Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKK-
beta links inflammation and tumorigenesis in a mouse 
model of colitis-associated cancer. Cell, 2004, 118, 
285-90. 
[82] Mattson, M.P.; Camandola, S. NF-kappaB in neu-
ronal plasticity and neurodegenerative disorders. J. 
Clin. Invest., 2001, 107, 247-54. 
[83] Memet, S. NF-kappaB functions in the nervous sys-
tem: from development to disease. Biochem. Pharma-
col., 2006, 72, 1180-95. 
[84] O'Neill, L.A.; Kaltschmidt, C. NF-kappa B: a crucial 
transcription factor for glial and neuronal cell func-
tion. Trends Neurosci., 1997, 20, 252-58. 
[85] Kaltschmidt, C.; Kaltschmidt, B.; Baeuerle, P.A. 
Brain synapses contain inducible forms of the tran-
scription factor NF-kappa B. Mech. Dev., 1993, 43, 
135-47. 
[86] Schneider, A.; Martin-Villalba, A.; Weih, F.; Vogel, 
J.; Wirth, T.; Schwaninger, M. NF-kappaB is acti-
vated and promotes cell death in focal cerebral 
ischemia. Nat. Med., 1999, 5, 554-59. 
[87] Ullrich, O.; Diestel, A.; Bechmann, I.; Homberg, M.; 
Grune, T.; Hass, R.; Nitsch, R. Turnover of oxida-
tively damaged nuclear proteins in BV-2 microglial 
cells is linked to their activation state by poly-ADP-
ribose polymerase. FASEB J., 2001, 15, 1460-62. 
[88] Gveric, D.; Kaltschmidt, C.; Cuzner, M.L.; Newcom-
be, J. Transcription factor NF-kappaB and inhibitor I 
kappaBalpha are localized in macrophages in active 
multiple sclerosis lesions. J. Neuropathol. Exp. Neu-
rol., 1998, 57, 168-78. 
[89] Nicholas, R.S.; Wing, M.G.; Compston, A. Nonacti-
vated microglia promote oligodendrocyte precursor 
survival and maturation through the transcription fac-
tor NF-kappa B. Eur. J. Neurosci., 2001, 13, 959-67. 
[90] Vollgraf, U.; Wegner, M.; Richter-Landsberg, C. Ac-
tivation of AP-1 and nuclear factor-kappaB transcrip-
tion factors is involved in hydrogen peroxide-induced 
apoptotic cell death of oligodendrocytes. J. Neuro-
chem., 1999, 73, 2501-09. 
[91] Bonetti, B.; Stegagno, C.; Cannella, B.; Rizzuto, N.; 
Moretto, G.; Raine, C.S. Activation of NF-kappaB 
and c-jun transcription factors in multiple sclerosis le-
sions. Implications for oligodendrocyte pathology. 
Am. J. Pathol., 1999, 155, 1433-38. 
[92] Achiron, A.; Gurevich, M. Peripheral blood gene ex-
pression signature mirrors central nervous system dis-
ease: the model of multiple sclerosis. Autoimmun. 
Rev., 2006, 5, 517-22. 
[93] Chabas, D.; Baranzini, S.E.; Mitchell, D.; Bernard, 
C.C.; Rittling, S.R.; Denhardt, D.T.; Sobel, R.A.; 
Lock, C.; Karpuj, M.; Pedotti, R.; Heller, R.; Oksen-
berg, J.R.; Steinman, L. The influence of the proin-
flammatory cytokine, osteopontin, on autoimmune 
demyelinating disease. Science, 2001, 294, 1731-35. 
[94] Lindberg, R.L.; De Groot, C.J.; Certa, U.; Ravid, R.; 
Hoffmann, F.; Kappos, L.; Leppert, D. Multiple scle-
rosis as a generalized CNS disease--comparative mi-
croarray analysis of normal appearing white matter 
and lesions in secondary progressive MS. J. Neuro-
immunol., 2004, 152, 154-67. 
[95] Mycko, M.P.; Papoian, R.; Boschert, U.; Raine, C.S.; 
Selmaj, K.W. cDNA microarray analysis in multiple 
sclerosis lesions: detection of genes associated with 
disease activity. Brain, 2003, 126, 1048-57. 
[96] Mycko, M.P.; Papoian, R.; Boschert, U.; Raine, C.S.; 
Selmaj, K.W. Microarray gene expression profiling of 
chronic active and inactive lesions in multiple sclero-
sis. Clin. Neurol. Neurosurg., 2004, 106, 223-29. 
[97] Satoh, J.I.; Obayashi, S.; Misawa, T.; Tabunoki, H.; 
Yamamura, T.; Arima, K.; Konno, H. Neuromyelitis 
NF-?B, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6     553 
optica/Devic's disease: Gene expression profiling of 
brain lesions. Neuropathology, 2008, 28, 561-xxx. 
[98] Lock, C.; Hermans, G.; Pedotti, R.; Brendolan, A.; 
Schadt, E.; Garren, H.; Langer-Gould, A.; Strober, S.; 
Cannella, B.; Allard, J.; Klonowski, P.; Austin, A.; 
Lad, N.; Kaminski, N.; Galli, S.J.; Oksenberg, J.R.; 
Raine, C.S.; Heller, R.; Steinman, L. Gene-
microarray analysis of multiple sclerosis lesions y-
ields new targets validated in autoimmune encepha-
lomyelitis. Nat. Med., 2002, 8, 500-08. 
[99] Tajouri, L.; Mellick, A.S.; Ashton, K.J.; Tannenberg, 
A.E.; Nagra, R.M.; Tourtellotte, W.W.; Griffiths, 
L.R. Quantitative and qualitative changes in gene ex-
pression patterns characterize the activity of plaques 
in multiple sclerosis. Brain Res. Mol. Brain Res., 
2003, 119, 170-83. 
[100] Flores, N.; Duran, C.; Blasco, M.R.; Puerta, C.; Do-
rado, B.; Garcia-Merino, A.; Ballester, S. NFkappaB 
and AP-1 DNA binding activity in patients with mul-
tiple sclerosis. J. Neuroimmunol., 2003, 135, 141-47. 
[101] Eggert, M.; Goertsches, R.; Seeck, U.; Dilk, S.; 
Neeck, G.; Zettl, U.K. Changes in the activation level 
of NF-kappa B in lymphocytes of MS patients during 
glucocorticoid pulse therapy. J. Neurol. Sci., 2008, 
264, 145-50. 
[102] Achiron, A.; Feldman, A.; Mandel, M.; Gurevich, M. 
Impaired expression of peripheral blood apoptotic-
related gene transcripts in acute multiple sclerosis re-
lapse. Ann. NY Acad. Sci., 2007, 1107, 155-67. 
[103] Bomprezzi, R.; Ringner, M.; Kim, S.; Bittner, M.L.; 
Khan, J.; Chen, Y.; Elkahloun, A.; Yu, A.; Bielekova, 
B.; Meltzer, P.S.; Martin, R.; McFarland, H.F.; Trent, 
J.M. Gene expression profile in multiple sclerosis pa-
tients and healthy controls: identifying pathways rele-
vant to disease. Hum. Mol. Genet., 2003, 12, 2191-99. 
[104] Aktas, O.; Prozorovski, T.; Smorodchenko, A.; Sa-
vaskan, N.E.; Lauster, R.; Kloetzel, P.M.; Infante-
Duarte, C.; Brocke, S.; Zipp, F. Green tea epigalloca-
techin-3-gallate mediates T cellular NF-kappa B inhi-
bition and exerts neuroprotection in autoimmune en-
cephalomyelitis. J. Immunol., 2004, 173, 5794-800. 
[105] Bettelli, E.; Dastrange, M.; Oukka, M. Foxp3 inter-
acts with nuclear factor of activated T cells and NF-
kappa B to repress cytokine gene expression and ef-
fector functions of T helper cells. Proc. Natl. Acad. 
Sci. USA, 2005, 102, 5138-43. 
[106] Cvetkovic, I.; Miljkovic, D.; Vuckovic, O.; Harhaji, 
L.; Nikolic, Z.; Trajkovic, V.; Mostarica Stojkovic, 
M. Axol activates inducible nitric oxide synthase in 
rat astrocytes: the role of MAP kinases and NF-
kappaB. Cell Mol. Life Sci., 2004, 61, 1167-75. 
[107] Dasgupta, S.; Jana, M.; Zhou, Y.; Fung, Y.K.; Ghosh, 
S.; Pahan, K. Antineuroinflammatory effect of NF-
kappaB essential modifier-binding domain peptides in 
the adoptive transfer model of experimental allergic 
encephalomyelitis. J. Immunol., 2004, 173, 1344-54. 
[108] Dasgupta, S.; Zhou, Y.; Jana, M.; Banik, N.L.; Pahan, 
K. Sodium phenylacetate inhibits adoptive transfer of 
experimental allergic encephalomyelitis in SJL/J mice 
at multiple steps. J. Immunol., 2003, 170, 3874-82. 
[109] Du, C.; Bright, J.J.; Sriram, S. Inhibition of CD40 
signaling pathway by tyrphostin A1 reduces secretion 
of IL-12 in macrophage, Th1 cell development and 
experimental allergic encephalomyelitis in SJL/J 
mice. J. Neuroimmunol., 2001, 114, 69-79. 
[110] Du, C.; Khalil, M.W.; Sriram, S. Administration of 
dehydroepiandrosterone suppresses experimental al-
lergic encephalomyelitis in SJL/J mice. J. Immunol., 
2001, 167, 7094-101. 
[111] Dunn, S.E.; Ousman, S.S.; Sobel, R.A.; Zuniga, L.; 
Baranzini, S.E.; Youssef, S.; Crowell, A.; Loh, J.; 
Oksenberg, J.; Steinman, L. Peroxisome proliferator-
activated receptor (PPAR) alpha expression in T cells 
mediates gender differences in development of T cell-
mediated autoimmunity. J. Exp. Med., 2007, 204, 
321-30. 
[112] Heneka, M.T.; Sharp, A.; Murphy, P.; Lyons, J.A.; 
Dumitrescu, L.; Feinstein, D.L. The heat shock res-
ponse reduces myelin oligodendrocyte glycoprotein-
induced experimental autoimmune encephalomyelitis 
in mice. J. Neurochem., 2001, 77, 568-79. 
[113] Hilliard, B.; Samoilova, E.B.; Liu, T.S.; Rostami, A.; 
Chen, Y. Experimental autoimmune encephalomyeli-
tis in NF-kappa B-deficient mice:roles of NF-kappa B 
in the activation and differentiation of autoreactive T 
cells. J. Immunol., 1999, 163, 2937-43. 
[114] Hilliard, B.A.; Mason, N.; Xu, L.; Sun, J.; Lam-
hamedi-Cherradi, S.E.; Liou, H.C.; Hunter, C.; Chen, 
Y.H. Critical roles of c-Rel in autoimmune inflamma-
tion and helper T cell differentiation. J. Clin. Invest., 
2002, 110, 843-50. 
[115] Ho, P.P.; Fontoura, P.; Ruiz, P.J.; Steinman, L.; Gar-
ren, H. An immunomodulatory GpG oligonucleotide 
for the treatment of autoimmunity via the innate and 
adaptive immune systems. J. Immunol., 2003, 171, 
4920-26. 
[116] Hur, E.M.; Youssef, S.; Haws, M.E.; Zhang, S.Y.; 
Sobel, R.A.; Steinman, L. Osteopontin-induced re-
lapse and progression of autoimmune brain disease 
through enhanced survival of activated T cells. Nat. 
Immunol., 2007, 8, 74-83. 
[117] Iruretagoyena, M.I.; Sepulveda, S.E.; Lezana, J.P.; 
Hermoso, M.; Bronfman, M.; Gutierrez, M.A.; Jaco-
belli, S.H.; Kalergis, A.M. Inhibition of nuclear fac-
tor-kappa B enhances the capacity of immature 
dendritic cells to induce antigen-specific tolerance in 
experimental autoimmune encephalomyelitis. J. 
Pharmacol. Exp. Ther., 2006, 318, 59-67. 
554      CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6 Yan and Greer 
[118] Kaltschmidt, B.; Sparna, T.; Kaltschmidt, C. Activa-
tion of NF-kappa B by reactive oxygen intermediates 
in the nervous system. Antioxid. Redox Signal, 1999, 
1, 129-44. 
[119] Kaltschmidt, C.; Kaltschmidt, B.; Lannes-Vieira, J.; 
Kreutzberg, G.W.; Wekerle, H.; Baeuerle, P.A.; 
Gehrmann, J. Transcription factor NF-kappa B is ac-
tivated in microglia during experimental autoimmune 
encephalomyelitis. J. Neuroimmunol., 1994, 55, 99-
106. 
[120] Martin-Saavedra, F.M.; Flores, N.; Dorado, B.; Egui-
luz, C.; Bravo, B.; Garcia-Merino, A.; Ballester, S. 
Beta-interferon unbalances the peripheral T cell 
proinflammatory response in experimental autoim-
mune encephalomyelitis. Mol. Immunol., 2007, 44, 
3597-607. 
[121] Mohamed, A.; Afridi, D.M.; Garani, O.; Tucci, M. 
Hymoquinone inhibits the activation of NF-kappaB in 
the brain and spinal cord of experimental autoimmune 
encephalomyelitis. Biomed. Sci. Instrum., 2005, 41, 
388-93. 
[122] Moreno, B.; Hevia, H.; Santamaria, M.; Sepulcre, J.; 
Munoz, J.; Garcia-Trevijano, E.R.; Berasain, C.; Cor-
rales, F.J.; Avila, M.A.; Villoslada, P. Meth-
ylthioadenosine reverses brain autoimmune disease. 
Ann. Neurol., 2006, 60, 323-34. 
[123] Ousman, S.S.; Tomooka, B.H.; van Noort, J.M.; 
Wawrousek, E.F.; O'Connor, K.C.; Hafler, D.A.; 
Sobel, R.A.; Robinson, W.H.; Steinman, L. Protective 
and therapeutic role for alphaB-crystallin in autoim-
mune demyelination. Nature, 2007, 448, 474-79. 
[124] Pahan, K.; Schmid, M. Activation of nuclear factor-
kB in the spinal cord of experimental allergic en-
cephalomyelitis. Neurosci. Lett., 2000, 287, 17-20. 
[125] Prasad, R.; Giri, S.; Nath, N.; Singh, I.; Singh, A.K. 
Inhibition of phosphoinositide 3 kinase-Akt (protein 
kinase B)-nuclear factor-kappa B pathway by lovasta-
tin limits endothelial-monocyte cell interaction. J. 
Neurochem., 2005, 94, 204-14. 
[126] Prasad, R.; Giri, S.; Nath, N.; Singh, I.; Singh, A.K. 
5-aminoimidazole-4-carboxamide-1-beta-4-
ribofuranoside attenuates experimental autoimmune 
encephalomyelitis via modulation of endothelial-
monocyte interaction. J. Neurosci. Res., 2006, 84, 
614-25. 
[127] Quinones, M.P.; Kalkonde, Y.; Estrada, C.A.; Jime-
nez, F.; Ramirez, R.; Mahimainathan, L.; Mummidi, 
S.; Choudhury, G.G.; Martinez, H.; Adams, L.; Mack, 
M.; Reddick, R.L.; Maffi, S.; Haralambous, S.; Prob-
ert, L.; Ahuja, S.K.; Ahuja, S.S. Role of astrocytes 
and chemokine systems in acute TNFalpha induced 
demyelinating syndrome: CCR2-dependent signals 
promote astrocyte activation and survival via NF-
kappaB and Akt. Mol. Cell Neurosci., 2008, 37, 96-
109. 
[128] Rolls, A.; Cahalon, L.; Bakalash, S.; Avidan, H.; 
Lider, O.; Schwartz, M. A sulfated disaccharide de-
rived from chondroitin sulfate proteoglycan protects 
against inflammation-associated neurodegeneration. 
FASEB J., 2006, 20, 547-49. 
[129] Sanchez, A.J.; Puerta, C.; Ballester, S.; Gonzalez, P.; 
Arriaga, A.; Garcia-Merino, A. Rolipram impairs NF-
kappaB activity and MMP-9 expression in experi-
mental autoimmune encephalomyelitis. J. Neuroim-
munol., 2005, 168, 13-20. 
[130] Wang, Z.; Qiu, J.; Guo, T.B.; Liu, A.; Wang, Y.; Li, 
Y.; Zhang, J.Z. Anti-inflammatory properties and 
regulatory mechanism of a novel derivative of artem-
isinin in experimental autoimmune encephalomyeli-
tis. J. Immunol., 2007, 179, 5958-65. 
[131] Yin, P.; Luby, T.M.; Chen, H.; Etemad-Moghadam, 
B.; Lee, D.; Aziz, N.; Ramstedt, U.; Hedley, M.L. 
Generation of expression constructs that secrete bio-
active alphaMSH and their use in the treatment of ex-
perimental autoimmune encephalomyelitis. Gene 
Ther., 2003, 10, 348-55. 
[132] van Loo, G.; De Lorenzi, R.; Schmidt, H.; Huth, M.; 
Mildner, A.; Schmidt-Supprian, M.; Lassmann, H.; 
Prinz, M.R.; Pasparakis, M. Inhibition of transcription 
factor NF-kappaB in the central nervous system ame-
liorates autoimmune encephalomyelitis in mice. Nat. 
Immunol., 2006, 7, 954-61. 
[133] Elliott, P.J.; Zollner, T.M.; Boehncke, W.H. Protea-
some inhibition: a new anti-inflammatory strategy. J. 
Mol. Med., 2003, 81, 235-45. 
[134] Paintlia, A.S.; Paintlia, M.K.; Singh, I.; Singh, A.K. 
IL-4-induced peroxisome proliferator-activated recep-
tor gamma activation inhibits NF-kappaB trans acti-
vation in central nervous system (CNS) glial cells and 
protects oligodendrocyte progenitors under neuroin-
flammatory disease conditions: implication for CNS-
demyelinating diseases. J. Immunol., 2006, 176, 
4385-98. 
[135] Lovett-Racke, A.E.; Hussain, R.Z.; Northrop, S.; 
Choy, J.; Rocchini, A.; Matthes, L.; Chavis, J.A.; Di-
ab, A.; Drew, P.D.; Racke, M.K. Peroxisome prolife-
rator-activated receptor alpha agonists as therapy for 
autoimmune disease. J. Immunol., 2004, 172, 5790-
98. 
[136] Olerup, O.; Hillert, J. HLA class II-associated genetic 
susceptibility in multiple sclerosis: a critical evalua-
tion. Tissue antigens, 1991, 38 1-15. 
[137] Svejgaard, A. The immunogenetics of multiple scle-
rosis. Immunogenetics, 2008, 60, 275-86. 
[138] The MHC sequencing consortium. Complete se-
quence and gene map of a human major histocom-
patibility complex. The MHC sequencing consortium. 
Nature, 1999, 401, 921-23. 
[139] Huang, C.J.; Nazarian, R.; Lee, J.; Zhao, P.M.; Espi-
nosa-Jeffrey, A.; de Vellis, J. Tumor necrosis factor 
NF-?B, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6     555 
modulates transcription of myelin basic protein gene 
through nuclear factor kappa B in a human oligoden-
droglioma cell line. Int. J. Dev. Neurosci., 2002, 20, 
289-96. 
[140] Allcock, R.J.; de la Concha, E.G.; Fernandez-
Arquero, M.; Vigil, P.; Conejero, L.; Arroyo, R.; 
Price, P. Susceptibility to multiple sclerosis mediated 
by HLA-DRB1 is influenced by a second gene te-
lomeric of the TNF cluster. Hum. Immunol., 1999, 60, 
1266-73. 
[141] Garcia-Merino, A.; Alper, C.A.; Usuku, K.; Marcus-
Bagley, D.; Lincoln, R.; Awdeh, Z.; Yunis, E.J.; Eis-
enbarth, G.S.; Brink, S.J.; Hauser, S.L. Tumor necro-
sis factor (TNF) microsatellite haplotypes in relation 
to extended haplotypes, susceptibility to diseases as-
sociated with the major histocompatibility complex 
and TNF secretion. Hum. Immunol., 1996, 50, 11-21. 
[142] Albertella, M.R.; Campbell, R.D. Characterization of 
a novel gene in the human major histocompatibility 
complex that encodes a potential new member of the I 
kappa B family of proteins. Hum. Mol. Genet., 1994, 
3, 793-99. 
[143] Shiina, T.; Tamiya, G.; Oka, A.; Yamagata, T.; Ya-
magata, N.; Kikkawa, E.; Goto, K.; Mizuki, N.; Wa-
tanabe, K.; Fukuzumi, Y.; Taguchi, S.; Sugawara, C.; 
Ono, A.; Chen, L.; Yamazaki, M.; Tashiro, H.; Ando, 
A.; Ikemura, T.; Kimura, M.; Inoko, H. Nucleotide 
sequencing analysis of the 146-kilobase segment 
around the IkBL and MICA genes at the centromeric 
end of the HLA class I region. Genomics, 1998, 47, 
372-82. 
[144] Allcock, R.J.; Christiansen, F.T.; Price, P. The central 
MHC gene IKBL carries a structural polymorphism 
that is associated with HLA-A3, B7, DR15. Immuno-
genetics, 1999, 49, 660-65. 
[145] Miterski, B.; Bohringer, S.; Klein, W.; Sindern, E.; 
Haupts, M.; Schimrigk, S.; Epplen, J.T. Inhibitors in 
the NFkappaB cascade comprise prime candidate 
genes predisposing to multiple sclerosis, especially in 
selected combinations. Genes Immun., 2002, 3, 211-
19. 
[146] Castiblanco, J.; Anaya, J.-M. The IkappaBL gene 
polymorphism influences risk of acquiring systemic 
lupus erythematosus and Sjögren's syndrome. Human 
Immunol., 2008, 69, 45-61. 
[147] Hamamcioglu, K.; Reder, A.T. Interferon-beta regu-
lates cytokines and BDNF: greater effect in relapsing 
than in progressive multiple sclerosis. Mult. Scler., 
2007, 13, 459-70. 
[148] Wandinger, K.P.; Sturzebecher, C.S.; Bielekova, B.; 
Detore, G.; Rosenwald, A.; Staudt, L.M.; McFarland, 
H.F.; Martin, R. Complex immunomodulatory effects 
of interferon-beta in multiple sclerosis include the 
upregulation of T helper 1-associated marker genes. 
Ann. Neurol., 2001, 50, 349-57. 
[149] Kim, M.O.; Si, Q.; Zhou, J.N.; Pestell, R.G.; Brosnan, 
C.F.; Locker, J.; Lee, S.C. Interferon-beta activates 
multiple signaling cascades in primary human micro-
glia. J. Neurochem. 2002, 81, 1361-71. 
[150] Ma, X.Y.; Wang, H.; Ding, B.; Zhong, H.; Ghosh, S.; 
Lengyel, P. The interferon-inducible p202a protein 
modulates NF-kappaB activity by inhibiting the bind-
ing to DNA of p50/p65 heterodimers and p65 ho-
modimers while enhancing the binding of p50 
homodimers. J. Biol. Chem., 2003, 278, 23008-19. 
[151] Dale, E.; Davis, M.; Faustman, D.L. A role for tran-
scription factor NF-kappaB in autoimmunity: possible 
interactions of genes, sex, and the immune response. 
Adv. Physiol. Educ., 2006, 30, 152-58. 
[152] Payne, D.N.; Adcock, I.M. Molecular mechanisms of 
corticosteroid actions. Paediatr. Respir. Rev., 2001, 2, 
145-50. 
[153] Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, 
R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; 
Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; 
Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; 
Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-
dependent Rac1 activation is the molecular target of 
azathioprine in primary human CD4+ T lymphocytes. 
J. Clin. Invest., 2003, 111, 1133-45. 
[154] Li, Q.Q.; Bever, C.T. Glatiramer acetate blocks inter-
leukin-1-dependent nuclear factor-kappaB activation 
and RANTES expression in human U-251 MG astro-
glial cells. Brain Res. Mol. Brain Res., 2001, 87, 48-
60. 
[155] Glabinski, A.R.; Bielecki, B.; Kawczak, J.A.; Tuohy, 
V.K.; Selmaj, K.; Ransohoff, R.M. Treatment with 
soluble tumor necrosis factor receptor 
(sTNFR):Fc/p80 fusion protein ameliorates relapsing-
remitting experimental autoimmune encephalomyeli-
tis and decreases chemokine expression. Autoimmu-
nity, 2004, 37, 465-71. 
[156] Selmaj, K.; Raine, C.S.; Cross, A.H. Anti-tumor ne-
crosis factor therapy abrogates autoimmune demyeli-
nation. Ann. Neurol., 1991, 30, 694-700. 
[157] van Oosten, B.W.; Barkhof, F.; Truyen, L.; Boringa, 
J.B.; Bertelsmann, F.W.; von Blomberg, B.M.E.; 
Woody, J.N.; Hartung, H.P.; Polman, C.H. Increased 
MRI activity and immune activation in two multiple 
sclerosis patients treated with the monoclonal anti-
tumor necrosis factor antibody cA2. Neurology, 1996, 
47, 1531-34. 
[158] The Lenercept Multiple Sclerosis Study Group and 
The University of British Columbia MS/MRI Analy-
sis Group, TNF neutralization in MS: results of a ran-
domized, placebo-controlled multicenter study. The 
Lenercept Multiple Sclerosis Study Group and The 
University of British Columbia MS/MRI Analysis 
Group. Neurology, 1999, 53, 457-65. 
556      CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6 Yan and Greer 
[159] Plummer, S.M.; Holloway, K.A.; Manson, M.M.; 
Munks, R.J.; Kaptein, A.; Farrow, S.; Howells, L. In-
hibition of cyclo-oxygenase 2 expression in colon 
cells by the chemopreventive agent curcumin in-
volves inhibition of NF-kappaB activation via the 
NIK/IKK signalling complex. Oncogene, 1999, 18, 
6013-20. 
[160] Chearwae, W.; Bright, J. 15-deoxy-Delta(12,14)-
prostaglandin J(2) and curcumin modulate the expres-
sion of toll-like receptors 4 and 9 in autoimmune T 
lymphocyte. J. Clin. Immunol., 2008, 28, 558-70. 
[161] Greve, B.; Weissert, R.; Hamdi, N.; Bettelli, E.; 
Sobel, R.A.; Coyle, A.; Kuchroo, V.K.; Rajewsky, 
K.; Schmidt-Supprian, M. I kappa B kinase 2/beta de-
ficiency controls expansion of autoreactive T cells 
and suppresses experimental autoimmune encepha-
lomyelitis. J. Immunol., 2007, 179, 179-85. 
[162] Vanderlugt, C.L.; Rahbe, S.M.; Elliott, P.J.; Dal 
Canto, M.C.; Miller, S.D. Treatment of established 
relapsing experimental autoimmune encephalomyeli-
tis with the proteasome inhibitor PS-519. J. Autoim-
mun., 2000, 14, 205-11. 
[163] Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Targeting nu-
clear factor-kappa B activation pathway by thymo-
quinone: role in suppression of antiapoptotic gene 
products and enhancement of apoptosis. Mol. Cancer 
Res., 2008, 6, 1059-70. 
[164] Confavreux, C.; Hutchinson, M.; Hours, M.M.; 
Cortinovis-Tourniaire, P.; Moreau, T. Rate of preg-
nancy-related relapse in multiple sclerosis. Pregnancy 
in Multiple Sclerosis Group. N. Engl. J. Med., 1998, 
339, 285-91. 
[165] Salemi, G.; Callari, G.; Gammino, M.; Battaglieri, F.; 
Cammarata, E.; Cuccia, G.; D'Amelio, M.; Lupo, I.; 
Ragonese, P.; Savettieri, G. The relapse rate of multi-
ple sclerosis changes during pregnancy: a cohort stu-
dy. Acta Neurol. Scand., 2004, 110, 23-26. 
[166] Whitaker, J.N. Effects of pregnancy and delivery on 
disease activity in multiple sclerosis. N. Engl. J. Med., 
1998, 339, 339-40. 
[167] Vukusic, S.; Confavreux, C. Pregnancy and multiple 
sclerosis: the children of PRIMS. Clin. Neurol. Neu-
rosurg., 2006, 108, 266-70. 
[168] Zang, Y.C.; Halder, J.B.; Hong, J.; Rivera, V.M.; 
Zhang, J.Z. Regulatory effects of estriol on T cell mi-
gration and cytokine profile: inhibition of transcrip-
tion factor NF-kappa B. J. Neuroimmunol., 2002, 
124, 106-14. 
[169] Zhu, W.H.; Lu, C.Z.; Huang, Y.M.; Link, H.; Xiao, 
B.G. A putative mechanism on remission of multiple 
sclerosis during pregnancy: estrogen-induced in-
doleamine 2,3-dioxygenase by dendritic cells. Mult. 
Scler., 2007, 13, 33-40. 
[170] Mattson, M.P.; Culmsee, C.; Yu, Z.F. Apoptotic and 
antiapoptotic mechanisms in stroke. Cell Tissue Res., 
2000, 301, 173-87. 
[171] DeLuca, G.C.; Williams, K.; Evangelou, N.; Ebers, 
G.C.; Esiri, M.M. The contribution of demyelination 
to axonal loss in multiple sclerosis. Brain, 2006, 129, 
1507-16. 
[172] Breij, E.C.W.; Brink, B.P.; Veerhuis, R.; van den 
Berg, C.; Vloet, R.; Yan, R.; Dijkstra, C.D.; van der 
Valk, P.; Bö, L. Homogeneity of active demyelinating 
lesions in established multiple sclerosis. Ann. Neurol., 
2008, 63, 16-25. 
[173] Lucchinetti, C.; Brück, W.; Parisi, J.; Scheithauer, B.; 
Rodriguez, M.; Lassmann, H. Heterogeneity of multi-
ple sclerosis lesions: implications for the pathogenesis 
of demyelination. Ann. Neurol., 2000, 47, 707-17. 
[174] Sadatipour, B.T.; Greer, J.M.; Pender, M.P. Increased 
circulating antiganglioside antibodies in primary and 
secondary progressive multiple sclerosis. Ann. Neu-
rol., 1998, 44, 980-83. 
[175] Kutzelnigg, A.; Lassmann, H. Cortical demyelination 
in multiple sclerosis: a substrate for cognitive defi-
cits? J. Neurol. Sci., 2006, 245, 123-26. 
[176] Pender, M.P.; Csurhes, P.A.; Wolfe, N.P.; Hooper, 
K.D.; Good, M.F.; McCombe, P.A.; Greer, J.M. In-
creased circulating T cell reactivity to GM3 and 
GQ1b gangliosides in primary progressive multiple 
sclerosis. J. Clin. Neurosci., 2003, 10, 63-66. 
[177] Greer, J.M.; Csurhes, P.A.; Cameron, K.D.; 
McCombe, P.A.; Good, M.F.; Pender, M.P. Increased 
immunoreactivity to two overlapping peptides of 
myelin proteolipid protein in multiple sclerosis. 
Brain, 1997, 120 1447-60. 
[178] Goodin, D.S.; Frohman, E.M.; Garmany, G.P., Jr.; 
Halper, J.; Likosky, W.H.; Lublin, F.D.; Silberberg, 
D.H.; Stuart, W.H.; van den Noort, S. Disease modi-
fying therapies in multiple sclerosis: report of the 
Therapeutics and Technology Assessment Subcom-
mittee of the American Academy of Neurology and 
the MS Council for Clinical Practice Guidelines. Neu-
rology, 2002, 58, 169-78. 
[179] Penton-Rol, G.; Cervantes-Llanos, M.; Cabrera-
Gomez, J.A.; Alonso-Ramirez, R.; Valenzuela-Silva, 
C.; Rodriguez-Lara, R.; Montero-Casimiro, E.; Bello-
Rivero, I.; Lopez-Saura, P. Treatment with type I in-
terferons induces a regulatory T cell subset in periph-
eral blood mononuclear cells from multiple sclerosis 
patients. Int. Immunopharmacol., 2008, 8, 881-86. 
[180] Wingerchuk, D.M. Current evidence and therapeutic 
strategies for multiple sclerosis. Semin. Neurol., 2008, 
28, 56-66. 
[181] Ford, C.C.; Johnson, K.P.; Lisak, R.P.; Panitch, H.S.; 
Shifronis, G.; Wolinsky, J.S. A prospective open-
label study of glatiramer acetate: over a decade of 
NF-?B, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis CNS & Neurological Disorders - Drug Targets, 2008, Vol. 7, No. 6     557 
continuous use in multiple sclerosis patients. Mult. 
Scler., 2006, 12, 309-20. 
[182] Martinelli Boneschi, F.; Rovaris, M.; Johnson, K.P.; 
Miller, A.; Wolinsky, J.S.; Ladkani, D.; Shifroni, G.; 
Comi, G.; Filippi, M. Effects of glatiramer acetate on 
relapse rate and accumulated disability in multiple 
sclerosis: meta-analysis of three double-blind, ran-
domized, placebo-controlled clinical trials. Mult. 
Scler., 2003, 9, 349-55. 
[183] Munari, L.; Lovati, R.; Boiko, A. Therapy with 
glatiramer acetate for multiple sclerosis. Cochrane 
Database Syst. Rev., 2004, CD004678. 
[184] Wolinsky, J.S.; Narayana, P.A.; O'Connor, P.; Coyle, 
P.K.; Ford, C.; Johnson, K.; Miller, A.; Pardo, L.; 
Kadosh, S.; Ladkani, D. Glatiramer acetate in primary 
progressive multiple sclerosis: results of a multinatio-
nal, multicenter, double-blind, placebo-controlled tri-
al. Ann. Neurol., 2007, 61, 14-24. 
[185] Ghalie, R.G.; Edan, G.; Laurent, M.; Mauch, E.; Ei-
senman, S.; Hartung, H.P.; Gonsette, R.E.; Butine, 
M.D.; Goodkin, D.E. Cardiac adverse effects associa-
ted with mitoxantrone (Novantrone) therapy in pati-
ents with MS. Neurology, 2002, 59, 909-13. 
[186] Ghalie, R.G.; Mauch, E.; Edan, G.; Hartung, H.P.; 
Gonsette, R.E.; Eisenmann, S.; Le Page, E.; Butine, 
M.D.; De Goodkin, D.E. A study of therapy-related 
acute leukaemia after mitoxantrone therapy for mul-
tiple sclerosis. Mult. Scler., 2002, 8, 441-45. 
[187] Hartung, H.P.; Gonsette, R.; Konig, N.; Kwiecinski, 
H.; Guseo, A.; Morrissey, S.P.; Krapf, H.; Zwingers, 
T. Mitoxantrone in progressive multiple sclerosis: a 
placebo-controlled, double-blind, randomised, multi-
centre trial. Lancet, 2002, 360, 2018-25. 
[188] Kleinschmidt-DeMasters, B.K.; Tyler, K.L. Progres-
sive multifocal leukoencephalopathy complicating 
treatment with natalizumab and interferon beta-1a for 
multiple sclerosis. N. Engl. J. Med., 2005, 353, 369-
74. 
[189] Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hut-
chinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; 
Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; 
Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomi-
zed, placebo-controlled trial of natalizumab for re-
lapsing multiple sclerosis. N. Engl. J. Med., 2006, 
354, 899-910. 
[190] Rice, G.P.; Hartung, H.P.; Calabresi, P.A. Anti-
alpha4 integrin therapy for multiple sclerosis: mecha-
nisms and rationale. Neurology, 2005, 64, 1336-42. 
[191] Filippi, M.; Rocca, M.A.; Pagani, E.; Iannucci, G.; 
Sormani, M.P.; Fazekas, F.; Ropele, S.; Hommes, 
O.R.; Comi, G. European study on intravenous im-
munoglobulin in multiple sclerosis: results of mag-
netization transfer magnetic resonance imaging 
analysis. Arch. Neurol., 2004, 61, 1409-12. 
[192] Hommes, O.R.; Sorensen, P.S.; Fazekas, F.; Enri-
quez, M.M.; Koelmel, H.W.; Fernandez, O.; Pozzilli, 
C.; O'Connor, P. Intravenous immunoglobulin in sec-
ondary progressive multiple sclerosis: randomised 
placebo-controlled trial. Lancet, 2004, 364, 1149-56. 
 
 
Received: September 1, 2008 Revised: December 27, 2008 Accepted: December 29, 2008 
 
 
